[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2917
6. Schwartz RA, Rothenberg J: Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease. J Cutan Pathol; 2010 Dec;37(12):1251-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of breast within a benign melanocytic nevus in the context of cutaneous breast metastatic disease.
  • Metastatic breast cancer of skin may be seen in a number of forms.
  • We describe a patient with metastatic adenocarcinoma of breast within a benign melanocytic nevus and delineate this occurrence within the context of reviewing cutaneous breast metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 John Wiley & Sons A/S.
  • (PMID = 20002237.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


7. Al-Kalaldeh JZ, Abu-Dahab R, Afifi FU: Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells. Nutr Res; 2010 Apr;30(4):271-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volatile oil composition and antiproliferative activity of Laurus nobilis, Origanum syriacum, Origanum vulgare, and Salvia triloba against human breast adenocarcinoma cells.
  • In the present study, selected spices used in Jordan were chemically analyzed and investigated for their antiproliferative activity to the adenocarcinoma of breast cell line (MCF7).
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiosperms / chemistry. Antineoplastic Agents, Phytogenic / therapeutic use. Breast Neoplasms / drug therapy. Cell Proliferation / drug effects. Oils, Volatile / therapeutic use. Terpenes / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534330.001).
  • [ISSN] 1879-0739
  • [Journal-full-title] Nutrition research (New York, N.Y.)
  • [ISO-abbreviation] Nutr Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Oils, Volatile; 0 / Plant Extracts; 0 / Rhodamines; 0 / Terpenes; 2609-88-3 / lissamine rhodamine B
  •  go-up   go-down


8. Stover TC, Sharma A, Robertson GP, Kester M: Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin Cancer Res; 2005 May 1;11(9):3465-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.
  • Here, we report that the systemic i.v. delivery of C6-ceramide (C6) in a pegylated liposomal formulation significantly limited the growth of solid tumors in a syngeneic BALB/c mouse tumor model of breast adenocarcinoma.
  • Confirming the therapeutic utility of i.v. liposomal-C6 administration, we also shown diminution of solid tumor growth in a human xenograft model of breast cancer.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / prevention & control. Animals. Apoptosis / drug effects. Caveolae / metabolism. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Dose-Response Relationship, Drug. Female. Humans. Injections, Intravenous. Liposomes. Mice. Mice, Inbred BALB C. Mice, Nude. Microscopy, Confocal. Mitochondria / metabolism. Neovascularization, Pathologic / pathology. Neovascularization, Pathologic / prevention & control. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867249.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL66371
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ceramides; 0 / Liposomes; 038753E78J / N-caproylsphingosine
  •  go-up   go-down


9. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr, Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest; 2005 Jan;35(1):60-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four peptide hormones decrease the number of human breast adenocarcinoma cells.
  • METHODS AND MATERIALS: These six hormones, each at their 1-microm concentrations, were evaluated for their ability to decrease the number and/or proliferation of breast adenocarcinoma cells in culture for 24, 48, 72, and 96 h.
  • RESULTS: Within 24 h, vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, atrial natriuretic peptide and 8-bromo-cyclic GMP, a cell-permeable analogue of their intracellular mediator cyclic GMP (each at 1 microm), decreased the number of breast adenocarcinoma cells 60%, 31%, 27%, 40%, and 31%, respectively.
  • There was no proliferation in the 3 days following this decrease in breast adenocarcinoma cell number.
  • Brain natriuretic peptide and CNP did not decrease the number of breast adenocarcinoma cells or inhibit their DNA synthesis.
  • Natriuretic peptide receptors-A and -C were present in the breast adenocarcinoma cells.
  • CONCLUSIONS: Four peptide hormones significantly decrease the number of human breast adenocarcinoma cells within 24 h and inhibit the proliferation of these cells for at least 96 h.
  • [MeSH-major] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Hormones / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638821.001).
  • [ISSN] 0014-2972
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / atrial natriuretic factor precursor (79-98); 0 / atrial natriuretic factor prohormone (1-30), human; 0 / atrial natriuretic factor prohormone (31-67); 114471-18-0 / Natriuretic Peptide, Brain; 127869-51-6 / Natriuretic Peptide, C-Type; 85637-73-6 / Atrial Natriuretic Factor; 9007-49-2 / DNA; E0399OZS9N / Cyclic AMP; EC 4.6.1.2 / Guanylate Cyclase; EC 4.6.1.2 / Receptors, Atrial Natriuretic Factor; EC 4.6.1.2 / atrial natriuretic factor receptor A; EC 4.6.1.2 / atrial natriuretic factor receptor C
  •  go-up   go-down


10. Xu WG, Yang K, Fang N, Dai D, Yu JP, Wei F, Song XY, Zhu YJ, Wang J, Men XY, Zhang Y: [Growing characteristic of breast adenocarcinoma suicide gene cell line T47D-tk and construction of subcutaneous xenografts]. Zhonghua Yi Xue Za Zhi; 2009 Feb 17;89(6):423-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growing characteristic of breast adenocarcinoma suicide gene cell line T47D-tk and construction of subcutaneous xenografts].
  • OBJECTIVE: To further identify the breast adenocarcinoma cell line T47D-tk stably expressing the suicide gene HSV1-tk, observe its growing characteristics, and establish an animal model of implanted breast adenocarcinoma.
  • METHODS: Retroviral vector of HSV1-tk gene and breast carcinoma cell line T47D-tk stably expressing the HSV1-tk gene were established.
  • Breast carcinoma cells of the lines T47D and T47D-tk were cultured, and observed by inverted microscope.
  • An animal model of implanted breast cancer has been successfully established.
  • [MeSH-major] Breast Neoplasms / genetics. Genes, Transgenic, Suicide / genetics. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19567126.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Moreno-Vega A, Chavarría N, Rubio J, Villandiego I, Estepa R, Gordon M, Salvador J, Jimenez E: Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain. J Clin Oncol; 2009 May 20;27(15_suppl):e21526

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary breast sarcoma: Clinical and retrospective analysis of cases from Jerez General Hospital, Spain.
  • : e21526 Background: Primary sarcomas of the breast (PBS) are a heterogeneous group of tumors from stromal breast, infrequent (0.1% of BC).
  • Diagnosis and treatment is unclear.
  • Contralateral low grade AS in one woman, and lung adenocarcinoma in the man, had been diagnosed 2 years later.
  • CONCLUSIONS: PBS are rare and difficult diagnosis tumors.
  • There are few series published, without prospective studies to evaluate an adequate therapy, diagnosis and valuable prognostic factors.
  • Our incidence was high, but the independent pathology analysis confirmed all histopathological diagnosis.
  • This review included novel IHC and IRM images, considered necessary for diagnosis and personalized treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963456.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Stevenson MM, Mostertz W, Acharya C, Walters K, Barry W, Tuchman S, Ready N, Onaitis M, Crawford J, Potti A: Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):11001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma.
  • METHODS: Using a large cohort of lung cancer cell lines with associated gene expression data, genes associated with an embryonic stem cell identity were used to develop a 'signature' representative of embryonic stemness (ES) activity specific to lung adenocarcinoma.
  • The ES signature was applied to three independent early (stage I - IIIa) lung adenocarcinoma data sets (N = 634) with clinically annotated gene expression data.
  • RESULTS: Using Bayesian regression analysis, a 100 gene signature representative of ES activity in lung adenocarcinoma was developed and validated in a leave-one-out-analysis.
  • The ES signature was not prognostic in prostate, ovarian, or breast adenocarcinomas.
  • Lung tumors (N=634) and adenocarcinoma cell lines (N=31) with ES were more resistant to cisplatin (p<0.0001 and p=0.0063, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964049.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Vinolas N, Magem M, Garrido P, Artal A, De Castro J, Campelo RG, Isla D, Felip E, Amador M, Rosell R: Lung cancer in women: The Spanish female-specific database WORLD 07. J Clin Oncol; 2009 May 20;27(15_suppl):8084

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous history of cancer 13.8% (breast 33.3%).
  • Current lung cancer histology (%): adenocarcinoma/BAC/squamous/large cell/NOS: 70.4/5.7/10.4/7.9/5.7.
  • CONCLUSIONS: According this series, 42% of Spanish lung cancer women are never smokers and 70.4% have adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962661.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Saji H, Tsuboi M, Miyajima K, Shimada Y, Ohira T, Ikeda N: Impact of number of resected and involved lymph nodes (LN) at the time of surgical resection on the survival of non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):7514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7514 Background: Total number of lymph-nodes has recently proven prognostic in early breast and colorectal cancer.
  • RESULTS: Demographics are as follows: median age: 65.0 (22-87yrs), sex: 547 males and 381 females, median follow-up time: 2.5 yrs, clinical stage: 765 stage I, 84 stage II and 76 stage III, histology: 684 adenocarcinoma, 182 squamous cell carcinoma, and 62 others, operation: 870 lobectomy, 42 bilobectomy and 16 pneumonectomy, mean number of resected LN: 15 (1-49), mean number of involved LN: 0.9 (0-22).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963485.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Fleischmann AM, Waser B, Reubi JC: Gastrin-releasing peptide receptors in the tumor vascular bed of various human cancers: high incidence in urinary tract cancers. J Clin Oncol; 2009 May 20;27(15_suppl):e14575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14575 Background: Tumoral Gastrin-releasing peptide (GRP) receptors are potential targets for diagnosis and therapy using radiolabeled or cytotoxic GRP analogs.
  • METHODS: Frequent human cancers from the breast (n=134), lung (n=57), prostate (n=50), kidney (n=32), colon (n=46), urinary tract (n=26) and biliary tract (n=23) were analyzed using in vitro GRP-receptor autoradiography on tissue sections with the <sup>125</sup>I-[Tyr<sup>4</sup>]-bombesin radioligand and/or the universal radioligand <sup>125</sup>I-[D-Tyr<sup>6</sup>, ß-Ala<sup>11</sup>, Phe<sup>13</sup>, Nle<sup>14</sup>]-bombesin(6-14).
  • Different tumor-types within a given site may have divergent prevalence of vascular GRP-receptors (e.g. lung: small cell cancer: 0%; adenocarcinoma: 59%; squamous carcinoma: 83%).
  • Also the vascular score varies widely, with highest score in urinary tract cancer (1.69), moderate scores in lung (0.91), colon (0.88), kidney (0.84) and biliary tract (0.69) cancers and low scores in breast (0.39) and prostate (0.14) cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963648.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • RESULTS: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38.
  • CONCLUSIONS: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Ho AS, Huang X, Cao H, Koong AC, Le QT: Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients. J Clin Oncol; 2009 May 20;27(15_suppl):4624

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating hypoxia-regulated miR-210 in pancreatic adenocarcinoma patients.
  • : 4624 Background: MicroRNAs (miRs) are small non-coding transcripts involved in many cellular mechanisms, including tumorigenesis. miR-210, in particular, has been shown to be induced by hypoxia, over-expressed in several different cancers, and correlated with adverse outcomes in breast cancer.
  • Its expression is significantly higher in the blood of pancreatic cancer patients compared to controls and may potentially serve as a useful biomarker for pancreatic cancer diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964211.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16119 Background: Id1, involved in cell differentiation, proliferation, tumor angiogenesis and metastasis, has recently showed to mediate lung MTS from breast cancer (PNAS 2007).
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ghiuzeli CM, Roussos ET, Wyckoff JB, Sun D, Wang Y, Patsialou T, Goswami S, Gertler FB, Condeelis JS: Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):1078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Mena isoforms as a surrogate for epithelial mesenchymal transformation and erlotinib resistance in breast carcinoma.
  • : 1078 Background: Epithelial to mesenchymal transition (EMT) is an important step in invasiveness and has been shown to correlate with metastatic potential in several cancer cell lines, including breast carcinoma.
  • Mena, a member of the enabled (ena)/vasodilator-stimulated phophoprotein (VASP) family, which controls cell motility, is upregulated in the invasive subpopulation of breast cancer cells.
  • METHODS: The animal models used were the polyoma middle T antigen (PyMT) transgenic mouse and severe combined immunodeficiency (SCID) xenografted tumors derived from injection with a human breast carcinoma line, MDA-MB-231, and a rat adenocarcinoma line, MTLn3, with forced expression of Mena<sup>INV</sup> and Mena11a.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961202.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Kumaraguruparan R, Chandra Mohan KV, Nagini S: Xenobiotic-metabolising enzymes in patients with adenocarcinoma of the breast: correlation with clinical stage and menopausal status. Breast; 2006 Feb;15(1):58-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Xenobiotic-metabolising enzymes in patients with adenocarcinoma of the breast: correlation with clinical stage and menopausal status.
  • Adenocarcinoma of the breast is the most common cancer in women worldwide and its incidence is increasing in most countries.
  • The present study was designed to evaluate the relationship between different clinical stages and menopausal status using the activity of phase I and II carcinogen-metabolising enzymes in breast cancer patients.
  • Fifty breast cancer patients clinically categorized as stage I, II and III, and as pre- and postmenopausal were chosen for the study.
  • Enhanced levels of cytochrome P450 and b(5) and phase II enzyme activity were observed in breast tumour tissues compared with the corresponding uninvolved adjacent tissues irrespective of clinical stage and menopausal status of the patients.
  • Our results suggest that the balance between phase I carcinogen activation and phase II detoxification systems may play an important role in the development of breast tumours.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Breast Neoplasms / enzymology. Breast Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002293.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Xenobiotics
  •  go-up   go-down


27. Xu WG, Dai D, Fang N, Song XY, Wang J, Zhu YJ, Men XY: [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice]. Zhonghua Yi Xue Za Zhi; 2009 Dec 29;89(48):3420-4
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular imaging for PET-CT reporter gene in breast adenocarcinoma (HSV1-tk) of subcutaneous xenografts in living nude mice].
  • OBJECTIVE: To study the in vitro accumulation of (18)F-FHBG, its in vivo distribution and (18)F-FHBG PET-CT imaging for reporter gene (HSV1-tk) in nude mice with a xenograft of breast adenocarcinoma.
  • METHODS: The in vitro uptake of (18)F-FHBG in tumor cells of T47D and T47D-tk and the distribution of (18)F-FHBG in normal Kunming mice and nude mice with breast adenocarcinoma xenograft were detected by well-type gamma counter.
  • Reporter gene PET-CT imaging with (18)F-FHBG was performed in nude mice with a xenograft of breast adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Breast Neoplasms / radionuclide imaging. Genes, Reporter. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223118.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 9-(4-fluoro-3-hydroxymethylbutyl)guanine; 0 / Fluorine Radioisotopes; 5Z93L87A1R / Guanine
  •  go-up   go-down


28. Vinothini G, Nagini S: Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast. Clin Chim Acta; 2010 Mar;411(5-6):368-74
MedlinePlus Health Information. consumer health - Menopause.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast.
  • BACKGROUND: Adenocarcinoma of the breast is the most common cancer worldwide and accounts for the highest morbidity and mortality.
  • The increasing global incidence of breast cancer emphasizes the need to understand the molecular mechanisms of breast tumorigenesis.
  • The present study was designed to correlate changes in xenobiotic-metabolizing enzymes (XME), oxidative stress and NFkappaB signaling with histological grading and menopausal status in breast cancer patients.
  • METHOD: Sixty breast cancer patients histologically categorized as grades I, II and III, and as pre- and postmenopausal were chosen for the study.
  • RESULTS: The breast tumors analyzed in the present study were characterized by increased activities of xenobiotic-metabolizing enzymes and enhanced oxidative damage to lipids, proteins, and DNA associated with variations in the expression of NFkappaB family members.
  • The magnitude of the changes was however more pronounced in premenopausal patients and in grade III breast tumors.
  • CONCLUSION: The present study delineates the correlation between XME-mediated oxidative stress and NFkappaB signaling that leads to the development of breast cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Cytochrome P-450 Enzyme System / metabolism. Menopause. NF-kappa B / metabolism. Oxidative Stress. Xenobiotics / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19995559.001).
  • [ISSN] 1873-3492
  • [Journal-full-title] Clinica chimica acta; international journal of clinical chemistry
  • [ISO-abbreviation] Clin. Chim. Acta
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Xenobiotics; 9035-51-2 / Cytochrome P-450 Enzyme System
  •  go-up   go-down


29. Saglam A, Can B: Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman. J Clin Pathol; 2005 Jan;58(1):87-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of lactating adenoma and invasive ductal adenocarcinoma of the breast in a pregnant woman.
  • A 36 year old pregnant woman was admitted to hospital complaining of an enlarging mass in her left breast.
  • Histopathological examination of the mastectomy specimen revealed a high grade infiltrating ductal adenocarcinoma intermixed with a lactating adenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Neoplasms, Multiple Primary / pathology. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2001 Dec;54(12):956-60 [11729217.001]
  • [Cites] Cancer. 1954 Mar;7(2):318-24 [13141224.001]
  • [Cites] Pathol Int. 2002 Mar;52(3):244-8 [11972869.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 3:iii31-6 [12821536.001]
  • [Cites] Virchows Arch. 2003 Jul;443(1):44-50 [12756565.001]
  • [Cites] Cancer. 1976 Jun;37(6):2891-905 [949710.001]
  • [Cites] Lancet. 1989 Feb 4;1(8632):252 [2563418.001]
  • [Cites] Acta Cytol. 1990 Jan-Feb;34(1):21-6 [2153326.001]
  • [Cites] Histopathology. 1993 May;22(5):481-5 [8344658.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1220-8 [8826943.001]
  • [Cites] J Clin Invest. 1997 Dec 1;100(11):2744-51 [9389738.001]
  • [Cites] Pharmacol Ther. 1998 Aug;79(2):169-78 [9749881.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Apr;13(2):311-32 [10363133.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Breast J. 2001 Sep-Oct;7(5):354-7 [11906446.001]
  • (PMID = 15623491.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770558
  •  go-up   go-down


30. Menezes AV, Lima MP, Mendonca JE, Haiter-Neto F, Kurita LM: Breast adenocarcinoma mimicking temporomandibular disorders: a case report. J Contemp Dent Pract; 2008;9(5):100-6
MedlinePlus Health Information. consumer health - Temporomandibular Joint Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast adenocarcinoma mimicking temporomandibular disorders: a case report.
  • AIM: The aim of this report is to present a case of a metastatic lesion in the mandible originating from a breast adenocarcinoma that was initially diagnosed as temporomandibular disorder (TMD).
  • Further clinical, radiological, and histological examinations coupled with a history of adenocarcinoma of the breast lead to a final diagnosis of a metastatic lesion in the right TMJ region.
  • Thus the dentist should be able to perform an adequate diagnosis and play an important role in the diagnostic phase of care that can lead to a useful palliation and an enhanced quality of the patient's life.
  • The challenge is to know and evaluate the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Mandibular Neoplasms / secondary. Temporomandibular Joint Disorders / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Mandibular Condyle / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633475.001).
  • [ISSN] 1526-3711
  • [Journal-full-title] The journal of contemporary dental practice
  • [ISO-abbreviation] J Contemp Dent Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Chvapil M: Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. Anticancer Drugs; 2005 Feb;16(2):201-10
Hazardous Substances Data Bank. (D)-PENICILLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens.
  • [MeSH-major] Adenocarcinoma / drug therapy. Aminopropionitrile / therapeutic use. Antineoplastic Agents / therapeutic use. Mammary Neoplasms, Animal / drug therapy. Penicillamine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. BETA-AMINOPROPIONITRILE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15655419.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Esters; 0 / Fibrillar Collagens; 151-18-8 / Aminopropionitrile; GNN1DV99GX / Penicillamine
  • [Number-of-references] 39
  •  go-up   go-down


32. Maounis N, Chorti M, Legaki S, Ellina E, Emmanouilidou A, Demonakou M, Tsiafaki X: Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature. Diagn Pathol; 2010;5:82
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis to the breast from an adenocarcinoma of the lung with extensive micropapillary component: a case report and review of the literature.
  • Breast metastasis from extra-mammary malignancy is rare.
  • The primary malignancies most commonly metastasizing to the breast are leukemia-lymphoma, and malignant melanoma.
  • We present a case of metastasis to the breast from a pulmonary adenocarcinoma, with extensive micropapillary component, diagnosed concomitantly with the primary tumor.
  • Additionally, on physical examination a poorly defined mass was noted in the upper outer quadrant of the left breast.
  • The patient underwent bronchoscopy, excisional breast biopsy and medical thoracoscopy.
  • By cytology, histology and immunohistochemistry primary lung adenocarcinoma with metastasis to the breast and parietal pleura was diagnosed.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Carcinoma, Papillary / secondary. Lung Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Chemotherapy, Adjuvant. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Mammography. Predictive Value of Tests. Thoracoscopy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2000 Apr;19(4):257-62 [10759349.001]
  • [Cites] J Surg Oncol. 2010 Feb 1;101(2):137-40 [20082359.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2259-66 [11745279.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Virchows Arch. 2002 Apr;440(4):353-61 [11956814.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2C):1825-6 [12820464.001]
  • [Cites] Med Oncol. 2003;20(2):181-4 [12835522.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2010 Mar;18(2):137-41 [19875957.001]
  • [Cites] Mod Pathol. 2010 May;23(5):654-61 [20173733.001]
  • [Cites] Diagn Pathol. 2010;5:37 [20565809.001]
  • [Cites] Am Surg. 2004 Apr;70(4):287-90 [15098776.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Cancer. 1972 Jun;29(6):1691-6 [4337956.001]
  • [Cites] AJR Am J Roentgenol. 1977 Oct;129(4):673-6 [409241.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] Acta Oncol. 1992;31(4):479 [1632985.001]
  • [Cites] South Med J. 1997 Oct;90(10):1063-4 [9347825.001]
  • [Cites] Australas Radiol. 1998 Feb;42(1):16-9 [9509597.001]
  • [Cites] Acta Chir Belg. 2005 Feb;105(1):59-61 [15790204.001]
  • [Cites] APMIS. 2006 May;114(5):381-5 [16725015.001]
  • [Cites] Breast J. 2006 Jul-Aug;12(4):366-7 [16848849.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Australas Radiol. 2007 Apr;51(2):133-8 [17419856.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):731-7 [17582626.001]
  • [Cites] South Med J. 2007 Aug;100(8):850-1 [17715476.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1333-41 [18042689.001]
  • [Cites] Arch Pathol Lab Med. 2008 Feb;132(2):239-43 [18251583.001]
  • [Cites] Am J Surg Pathol. 2008 Mar;32(3):426-32 [18300807.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):682-7 [18048381.001]
  • [Cites] Pathology. 2008 Jun;40(4):345-51 [18446623.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1299-301 [18505069.001]
  • [Cites] APMIS. 2009 Oct;117(10):762-7 [19775345.001]
  • [Cites] Gen Thorac Cardiovasc Surg. 2009 Oct;57(10):534-9 [19830516.001]
  • [Cites] Eur Radiol. 2001;11(9):1659-65 [11511887.001]
  • (PMID = 21167048.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] Adenocarcinoma of lung
  • [Other-IDs] NLM/ PMC3018363
  •  go-up   go-down


33. Chuang E, Wiener N, Christos P, Kessler R, Cobham M, Donovan D, Goldberg GL, Caputo T, Doyle A, Vahdat L, Sparano JA: Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol; 2010 Oct;21(10):2075-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary.
  • BACKGROUND: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer.
  • We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer.
  • METHODS: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients.
  • Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer.
  • This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Bridged-Ring Compounds / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Epothilones / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Polyethylene Glycols / administration & dosage. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Ixabepilone .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Mar;15(3):440-9 [14998846.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1289-98 [14977827.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):1-8 [15385103.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2325-33 [7757983.001]
  • [Cites] Nature. 1997 May 15;387(6630):268-72 [9153390.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1906-15 [9164201.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2726-34 [15837987.001]
  • [Cites] Cancer. 2005 May 1;103(9):1932-8 [15800893.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1633-42 [16575015.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3421-7 [17606971.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3407-14 [17606974.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Sep;5(8):673-5 [17927925.001]
  • [Cites] Anticancer Drugs. 2008 Jan;19(1):1-7 [18043124.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):890-6 [18281662.001]
  • [Cites] Ann Oncol. 2008 May;19(5):977-83 [18296423.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2223 [18445853.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):201-9 [18691173.001]
  • [Cites] Mol Cancer Ther. 2009 Feb;8(2):275-81 [19174552.001]
  • [Cites] Drugs. 2009 Jul 30;69(11):1471-81 [19634925.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4522-9 [19687336.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5906-10 [19858391.001]
  • [Cites] J Clin Oncol. 2010 Jul 10;28(20):3256-63 [20530276.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1037-47 [10964334.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Health Technol Assess. 2004 Feb;8(5):iii, xiii-xvi, 1-143 [14960257.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 May;53(5):452-7 [14749894.001]
  • (PMID = 20357034.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM-62204
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bridged-Ring Compounds; 0 / Epothilones; 0 / Taxoids; 0 / liposomal doxorubicin; 1605-68-1 / taxane; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; K27005NP0A / ixabepilone
  • [Other-IDs] NLM/ PMC2980936
  •  go-up   go-down


34. Brück P, Vilches Cisneros N, Ramos López E, Barboza Quintana O, Ancer Rodríguez J, Flores Gutiérrez JP: [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients]. Ginecol Obstet Mex; 2006 Oct;74(10):516-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2-Neu expression in ductal adenocarcinomas of the breast gland: correlation with histopathological parameters and estrogen receptors' expression in Mexican patients].
  • [Transliterated title] Expresión del Her2-Neu en el adenocarcinoma ductal de la glándula mamaria: correlación con parámetros histopatológicos y expresión de receptores estrogénicos en pacientes mexicanas.
  • BACKGROUND: Breast cancer is a general health problem that annually produces 400,000 deaths worldwide.
  • Its early diagnosis leads to high cure rates; nevertheless, in Mexico City this happens rarely.
  • Her2-Neu is an oncogene that is expressed on breast cancer cells, with aggressive behaviour and metastasis.
  • OBJECTIVE: To know the biology and distribution of Her2-Neu expression in Mexican breast cancer patients in order to evaluate its potential as a prognostic and predictive factor in the treatment of the breast cancer.
  • PATIENTS AND METHOD: In the cases of invasive ductal adenocarcinomas of the breast we compared by immunohistochemistry the Her2-Neu and estrogen receptor expressions with the histopathological characteristics.
  • RESULTS: We found 122 cases of breast adenocarcinoma, from which we evaluated 108 for fulfilling the selection criteria of invasive ductal adenocarcinoma.
  • CONCLUSIONS: Since the percentage of patients with Her2-Neu expression is high (36.1%) and there is a close relation between Her2-Neu expression, the tumour size and the presence of lymph node methastasis, the determination of the oncoprotein expression could allow a more detailed prognosis and the treatment with immunotherapy and anthracyclines in order to influence the course of the breast cancer cases.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Ductal, Breast / chemistry. Genes, erbB-2. Neoplasm Proteins / analysis. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21961357.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


35. Bassioukas K, Nakuci M, Dimou S, Kanellopoulou M, Alexis I: Zosteriform cutaneous metastases from breast adenocarcinoma. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):593-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zosteriform cutaneous metastases from breast adenocarcinoma.
  • Cutaneous metastases from breast adenocarcinoma are usually nodular, single or multiple.
  • We present a 54-year-old woman with cutaneous zosteriform nodular metastases on the right side of her thorax, and infiltration of the corresponding arm, 3 months after the excision of adenocarcinoma of her right breast.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Breast Neoplasms / surgery. Herpes Zoster / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Shingles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16164715.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


36. Layfield LJ, Lewis C: In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status. Anal Quant Cytol Histol; 2007 Aug;29(4):239-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ and invasive components of mammary adenocarcinoma: comparison of Her-2/neu status.
  • STUDY DESIGN: Using immunohistochemistry, this study compares the Her-2/neu status in the in situ and invasive components of 200 cases of ductal carcinoma of the breast.
  • CONCLUSION: Significant heterogeneity exists between Her-2/neu expression in the in situ component and invasive components of adenocarcinoma of the breast.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879632.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


37. Strik MW, Anders S, Barth M, Bärlehner E, Benecke C, Benhidjeb T: [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results]. Chirurg; 2007 Dec;78(12):1139-44
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total videoendoscopic thyroid resection by the axillobilateral breast approach. Operative method and first results].
  • [Transliterated title] Total-videoendoskopische Strumaresektion via "axillobilateral breast approach". Operative Technik und erste Ergebnisse.
  • BACKGROUND: The axillobilateral breast approach (ABBA) is a procedure allowing thyroid resection without scarring at the neck.
  • [MeSH-major] Adenocarcinoma, Follicular / surgery. Cysts / surgery. Endoscopes. Minimally Invasive Surgical Procedures / instrumentation. Surgical Instruments. Thyroid Diseases / surgery. Thyroid Neoplasms / surgery. Thyroid Nodule / surgery. Thyroidectomy / instrumentation. Video-Assisted Surgery / instrumentation
  • [MeSH-minor] Adult. Axilla / innervation. Axilla / surgery. Biopsy, Needle. Female. Humans. Intraoperative Complications / diagnosis. Intraoperative Complications / prevention & control. Middle Aged. Monitoring, Intraoperative / instrumentation. Recurrent Laryngeal Nerve Injuries. Reoperation. Thyroid Gland / pathology. Ultrasonic Therapy / instrumentation. Vocal Cord Paralysis / diagnosis. Vocal Cord Paralysis / prevention & control

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805497.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Asioli S, Marucci G, Ficarra G, Stephens M, Foschini MP, Ellis IO, Eusebi V: Polymorphous adenocarcinoma of the breast. Report of three cases. Virchows Arch; 2006 Jan;448(1):29-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphous adenocarcinoma of the breast. Report of three cases.
  • We report three cases of polymorphous adenocarcinoma (PLA) of the breast in 37-, 55- and 74-year-old women, respectively.
  • The tumours consist of monotonous cells showing a wide spectrum of growth patterns: solid nests, trabeculae, tubules, cribriform structures, strands and fascicles reminiscent of polymorphous low-grade adenocarcinoma of salivary glands.
  • To our knowledge, PLA has never been reported in the breast; therefore, this tumour should be added to the list of neoplastic lesions of the breasts that have the same features as those of the salivary glands.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220292.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


39. Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB, Hood L, Neelon R, Myles J, Budd GT, Moore HC, Andresen S, Crowe JP: Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol; 2007 Dec;16(4):207-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience.
  • We report our experience with primary FISH testing in 742 consecutive cases of breast cancer, in the calendar year 2006.
  • Eighty percent (595/742) of the breast cancer cases were not amplified for HER2 (HER2/CEP17=0.8-1.9), whereas 19% (142/742) of cases were HER2 amplified (HER2/CEP17>or=2.0).
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043283.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


40. Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR: The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol; 2005 Apr;36(4):348-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
  • Clinical and in vitro evidence supports the concept that human epidermal growth factor receptor-2 ( HER2 ) gene amplification prediction of response to anthracycline-based chemotherapy in breast cancer is not a direct effect of HER2 overexpression, but the result of coamplification of topoisomerase II-alpha ( TOP2A ).
  • One hundred thirty-eight cases of breast cancer HER2 gene amplified by 2-color FISH ( HER2 /CEP17) were reevaluated with a 3-color probe set ( HER2 /CEP17/ TOP2A ) to investigate the frequency of coamplification and deletion of TOP2A .
  • The current study demonstrates the complex interrelationship between the HER2 and TOP2A genes in breast cancer.
  • The clinical implications of TOP2A amplification and deletion in breast cancer need to be further defined.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Genes, erbB-2


41. Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol; 2005 Sep;29(9):1221-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
  • Breast carcinomas with amplification of HER2 on chromosome 17 are associated with HER2 protein overexpression, adversely affecting prognosis and predicting response to Herceptin therapy.
  • This impact was investigated in breast carcinomas identified by fluorescence in situ hybridization (FISH) to have a gain of chromosome 17 (CEP17+; n = 56), using a dual probe assay, which detects HER2 gene copy number and enumerates chromosome 17 (HER2/CEP17; Vysis).
  • These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. Chromosomes, Human, Pair 17 / genetics. Genes, erbB-2 / physiology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096413.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


42. Hegyesi H, Colombo L, Pállinger E, Tóth S, Boer K, Molnár V, Falus A: Impact of systemic histamine deficiency on the crosstalk between mammary adenocarcinoma and T cells. J Pharmacol Sci; 2007 Sep;105(1):66-73
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of systemic histamine deficiency on the crosstalk between mammary adenocarcinoma and T cells.
  • We assessed the phenotype and cytokine production of splenic lymphocytes in syngeneic HA-free (histidine decarboxylase knock-out) (HDC KO) and wild-type mice, inoculated subcutaneously with the LM2 murine breast cancer cell line.
  • In conclusion, the present study demonstrates that endogenous histamine stimulates the growth of breast adenocarcinoma tumor implants in mice by suppressing anti-tumor immunity.
  • [MeSH-major] Adenocarcinoma / physiopathology. Cell Communication / physiology. Histamine / deficiency. Mammary Neoplasms, Experimental / physiopathology. T-Lymphocytes, Regulatory / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17895589.001).
  • [ISSN] 1347-8613
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Cytokines; 0 / Forkhead Transcription Factors; 0 / Foxp3 protein, mouse; 0 / Interleukin-2 Receptor alpha Subunit; 0 / RNA, Messenger; 0 / T-Box Domain Proteins; 0 / T-box transcription factor TBX21; 820484N8I3 / Histamine; EC 4.1.1.22 / Histidine Decarboxylase
  •  go-up   go-down


43. Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G: Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat; 2010 Oct;123(3):679-89
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
  • Breast cancer resistance protein (BCRP/ABCG2), an ATP-binding cassette half transporter, confers multidrug resistance (MDR) to a series of antitumor agents such as mitoxantrone, daunorubicin, SN-38, and topotecan, and often limits the efficacy of chemotherapy.
  • In the present study, two plasmid vectors have been designed to express the wild-type full-length BCRP cDNA enforced driven by its endogenous promoter containing a functional ERE and a constitutive cytomegalovirus (CMV) promoter as control, respectively, which were transfected into estrogen-responsive MCF-7 and estrogen-independent MDA-MB-231 human breast adenocarcinoma cell lines.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Adenocarcinoma / genetics. Breast Neoplasms / genetics. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Neoplasm Proteins / genetics. Selective Estrogen Receptor Modulators / pharmacology. Toremifene / pharmacology. Transcription, Genetic / drug effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ESTRONE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19967559.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / Estrogen Receptor alpha; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Selective Estrogen Receptor Modulators; 2DI9HA706A / Estrone; 7NFE54O27T / Toremifene; BZ114NVM5P / Mitoxantrone
  •  go-up   go-down


44. Roque R, Pina A, Soares C, Martinho A, Messias H: [Splenic metastasis in ovary serous adenocarcinoma]. Acta Med Port; 2007 Nov-Dec;20(6):581-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic metastasis in ovary serous adenocarcinoma].
  • [Transliterated title] Metástases esplénicas no adenocarcinoma seroso do ovário.
  • The primary tumours more frequently related with splenic metastasis are lung, breast, gynaecologic, specially ovary tumours, colon, rectum and melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331703.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


45. Kumaraguruparan R, Kabalimoorthy J, Nagini S: Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast. Clin Biochem; 2005 Feb;38(2):154-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast.
  • OBJECTIVES: To evaluate the extent of lipid peroxidation and the antioxidant levels in breast cancer patients in relation to different clinical stages and menopausal status.
  • DESIGN AND METHODS: Fifty newly diagnosed women with adenocarcinoma of the breast were divided into different groups based on clinical staging and menopausal status.
  • RESULTS: Enhanced lipid peroxidation accompanied by significant elevation in enzymatic and nonenzymatic antioxidants was observed in breast tumor tissues compared to the corresponding uninvolved adjacent tissues irrespective of clinical stage and menopausal status of the patients.
  • [MeSH-major] Adenocarcinoma / pathology. Antioxidants / analysis. Breast Neoplasms / pathology. Lipid Peroxidation. Menopause

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Menopause.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15642278.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; EC 1.- / Oxidoreductases
  •  go-up   go-down


46. Granata A, Figura M, Gulisano S, Romeo G, Sicurezza E, Failla A, Scuderi R: [Central diabetes insipidus as a first manifestation of lung adenocarcinoma]. Clin Ter; 2007 Nov-Dec;158(6):519-22
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus as a first manifestation of lung adenocarcinoma].
  • [Transliterated title] Diabete insipido centrale come prima manifestazione di adenocarcinoma polmonare.
  • Metastases to the pituitary gland are absolutely rare, and they are generally secondary to pulmonary carcinoma in men and breast carcinoma in women.
  • Bronchoscopy and biopsy demonstrated a pulmonary adenocarcinoma.
  • Thus, we made a diagnosis of lung cancer with local and pituitary metastases.
  • In conclusion, in patients presenting with sudden onset of diabetes insipidus pituitary metastases should be taken in account in differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diabetes Insipidus / etiology. Lung Neoplasms / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / secondary
  • [MeSH-minor] Biopsy. Bronchoscopy. Diagnosis, Differential. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Polyuria / etiology. Thirst. Tomography, X-Ray Computed


47. Foroodi F, Duivenvoorden WC, Singh G: Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells. Anticancer Drugs; 2009 Feb;20(2):115-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
  • Commonly used chemotherapeutic agents for breast cancer treatment include cisplatin, doxorubicin, and paclitaxel.
  • Previously, we have shown that doxycycline can substantially reduce tumor burden in an animal model of breast cancer bone metastasis.
  • Human breast adenocarcinoma MDA-MB-231 cells were treated in vitro with each drug individually and in combination with doxycycline.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Breast Neoplasms / drug therapy. Doxycycline / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19209028.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; N12000U13O / Doxycycline; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Bertoli LF, Barton JC: Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer. Clin Breast Cancer; 2007 Aug;7(9):716-8
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of porphyria cutanea tarda after anastrozole treatment of breast cancer.
  • The PCT responded partially to the cessation of oral contraceptives and to phlebotomy therapy to maintain low iron stores, but only remitted after she received anastrozole therapy for management of adenocarcinoma of the breast at age 59 years.
  • The pertinence of HFE mutations, anastrozole and tamoxifen treatment, and chemotherapy to the development and management of PCT in women with breast cancer is discussed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Nitriles / therapeutic use. Porphyria Cutanea Tarda / drug therapy. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Porphyria.
  • Genetic Alliance. consumer health - Porphyria cutanea tarda.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919354.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Contraceptives, Oral; 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; 9007-73-2 / Ferritins
  • [Number-of-references] 28
  •  go-up   go-down


49. Bausero MA, Bharti A, Page DT, Perez KD, Eng JW, Ordonez SL, Asea EE, Jantschitsch C, Kindas-Muegge I, Ciocca D, Asea A: Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell. Tumour Biol; 2006;27(1):17-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell.
  • The 25-kDa heat shock protein (Hsp25) is associated with various malignancies and is expressed at high levels in biopsies as well as circulating in the serum of breast cancer patients.
  • In this study, we used RNA interference technology to silence the hsp25 gene in 4T1 breast adenocarcinoma cells, known as a poorly immunogenic, highly metastatic cell line.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Heat-Shock Proteins / biosynthesis. Heat-Shock Proteins / genetics. Neoplasm Metastasis / physiopathology. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. RNA Interference

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • [Cites] Tumour Biol. 2004 Sep-Dec;25(5-6):243-51 [15627887.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):967-71 [15705897.001]
  • [Cites] J Surg Oncol. 2005 Mar 15;89(4):207-10 [15726617.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):283-90 [9568646.001]
  • [Cites] Int J Cancer. 1997 Sep 4;72(5):871-7 [9311607.001]
  • [Cites] Free Radic Biol Med. 2004 Feb 15;36(4):429-44 [14975446.001]
  • [Cites] Photochem Photobiol Sci. 2003 Sep;2(9):899-903 [14560806.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Int J Cancer. 2003 Oct 10;106(6):879-86 [12918065.001]
  • [Cites] Cell Stress Chaperones. 2003 Spring;8(1):26-36 [12820652.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 16;304(4):801-6 [12727228.001]
  • [Cites] Melanoma Res. 2003 Apr;13(2):147-52 [12690297.001]
  • [Cites] Int J Hyperthermia. 2002 Nov-Dec;18(6):597-608 [12537758.001]
  • [Cites] Ann Med. 2002;34(6):480-8 [12523503.001]
  • [Cites] Cell Stress Chaperones. 2002 Apr;7(2):177-85 [12380685.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 9;296(1):201-5 [12147251.001]
  • [Cites] J Biochem. 2002 Jun;131(6):869-75 [12038984.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Eur J Pharm Sci. 2005 May;25(1):57-65 [15854801.001]
  • [Cites] Prog Mol Subcell Biol. 2002;28:205-18 [11908061.001]
  • [Cites] Int J Hyperthermia. 2001 Jul-Aug;17(4):347-56 [11471985.001]
  • [Cites] Cell Stress Chaperones. 2000 Nov;5(5):425-31 [11189447.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7099-105 [11156417.001]
  • [Cites] Nat Med. 2000 Apr;6(4):435-42 [10742151.001]
  • [Cites] J Biol Chem. 2002 Apr 26;277(17):15028-34 [11836257.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1263-6 [9607585.001]
  • [Cites] Invasion Metastasis. 1997;17(3):113-23 [9702938.001]
  • [Cites] Cell. 1998 Aug 7;94(3):353-62 [9708737.001]
  • [Cites] EMBO J. 1998 Nov 2;17(21):6124-34 [9799222.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1199-206 [9816288.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):595-603 [10027336.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • (PMID = 16340246.001).
  • [ISSN] 1010-4283
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA091889; United States / NCI NIH HHS / CA / R01 CA091889-05
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS15246; NLM/ PMC1764206
  •  go-up   go-down


50. Dutsch-Wicherek M, Popiela TJ, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet JP, Skladzien J, Tomaszewska R: Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett; 2005 Oct;26(5):567-74
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma.
  • The aim of our study was to evaluate the MT expression in head and neck squamous cells carcinoma and breast adenocarcinoma and their histologically healthy adjacent tissue.
  • MATERIALS AND METHODS: We have sampled 29 tissue samples in total derived from head and neck cancers and 29 samples of their clear surgical margins, 33 breast adenocarcinomas and 33 clear surgical margins.
  • RESULTS: MT expression was revealed in 85,7% of head and neck cancers and 94% of breast adenocarcinomas.
  • MT expression was statistically significantly higher in tumor adjacent tissue than in cancer tissue in cases with the presence of lymph node metastases in both, breast adenocarcinoma and head and neck squamous cell carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Metallothionein / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264399.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 9038-94-2 / Metallothionein
  •  go-up   go-down


51. Androutsopoulos VP, Mahale S, Arroo RR, Potter G: Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation. Oncol Rep; 2009 Jun;21(6):1525-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer effects of the flavonoid diosmetin on cell cycle progression and proliferation of MDA-MB 468 breast cancer cells due to CYP1 activation.
  • We have examined the ability of the natural flavone diosmetin to inhibit proliferation of breast adenocarcinoma MDA-MB 468 and normal breast MCF-10A cells and found that this compound is selective for the cancer cells with slight toxicity in the normal breast cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Breast Neoplasms / pathology. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cytochrome P-450 CYP1A1 / metabolism. Cytochrome P-450 Enzyme System / metabolism. Enzyme Activators / pharmacology. Flavonoids / pharmacology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Diosmetin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424633.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Activators; 0 / Flavonoids; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP1B1; KUX1ZNC9J2 / Luteolin; TWZ37241OT / diosmetin
  •  go-up   go-down


52. Kuo PL, Hsu YL, Lin TC, Lin LT, Chang JK, Lin CC: Casuarinin from the bark of Terminalia arjuna induces apoptosis and cell cycle arrest in human breast adenocarcinoma MCF-7 cells. Planta Med; 2005 Mar;71(3):237-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Casuarinin from the bark of Terminalia arjuna induces apoptosis and cell cycle arrest in human breast adenocarcinoma MCF-7 cells.
  • Casuarinin, a hydrolyzable tannin isolated from the bark of Terminalia arjuna L. (Combretaceae), was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells.
  • [MeSH-minor] Adenocarcinoma / prevention & control. Breast Neoplasms / prevention & control. Cell Line, Tumor / drug effects. Dose-Response Relationship, Drug. Female. Humans. Plant Bark. Plant Extracts / administration & dosage. Plant Extracts / pharmacology. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15770544.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Hydrolyzable Tannins; 0 / Plant Extracts; 0 / casuarinin
  •  go-up   go-down


53. Cosan DT, Bayram B, Soyocak A, Basaran A, Gunes HV, Degirmenci I, Musmul A: Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma. Cancer Biother Radiopharm; 2010 Oct;25(5):577-80
Hazardous Substances Data Bank. RESVERATROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of phenolic compounds in nitric oxide synthase activity in colon and breast adenocarcinoma.
  • This study aimed to determine the effects of resveratrol (RES) and tannic acid (TA), which are chemopreventive agents, on the nitric oxide synthase (NOS) levels that are effective for development of cancer in colon and breast cancer cell lines.
  • The CaCo-2 (human colon carcinoma cell line) and MCF-7 (Michigan Cancer Foundation-7; human breast adenocarcinoma cell line) cells were grown in the laboratory.
  • Results suggest that the phenolic compounds RES and TA have different effects on NOS enzyme activity of the colon and breast cancer cells.
  • [MeSH-major] Adenocarcinoma / enzymology. Anticarcinogenic Agents / pharmacology. Breast Neoplasms / enzymology. Colonic Neoplasms / enzymology. Nitric Oxide Synthase / metabolism. Phenols / pharmacology. Stilbenes / pharmacology. Tannins / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20874429.001).
  • [ISSN] 1557-8852
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Phenols; 0 / Stilbenes; 0 / Tannins; EC 1.14.13.39 / Nitric Oxide Synthase; Q369O8926L / resveratrol
  •  go-up   go-down


54. Chekhun VF, Kulik GI, Yurchenko OV, Tryndyak VP, Todor IN, Luniv LS, Tregubova NA, Pryzimirska TV, Montgomery B, Rusetskaya NV, Pogribny IP: Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett; 2006 Jan 8;231(1):87-93
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
  • In the present study, we used human MCF-7 breast adenocarcinoma cell line and its doxorubicin-resistant variant MCF-7/R to determine the role of alterations of DNA methylation of chemoresitance-related genes, such as multidrug resistance 1 (MDR1), glutathione-S-transferase (GSTpi), O(6)-methylguanine DNA methyltransferase (MGMT), and urokinase (Upa), in the development of drug resistance.
  • [MeSH-major] Adenocarcinoma / pathology. Antibiotics, Antineoplastic / pharmacology. Breast Neoplasms / pathology. DNA Methylation. Doxorubicin / pharmacology. Drug Resistance, Neoplasm / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356834.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione Transferase; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


55. Gaube F, Wölfl S, Pusch L, Werner U, Kroll TC, Schrenk D, Hartmann RW, Hamburger M: Effects of Leuzea carthamoides on human breast adenocarcinoma MCF-7 cells determined by gene expression profiling and functional assays. Planta Med; 2008 Nov;74(14):1701-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of Leuzea carthamoides on human breast adenocarcinoma MCF-7 cells determined by gene expression profiling and functional assays.
  • We investigated the effects of a lipophilic Leuzea root extract and the major phytoecdysteroid, 20-hydroxyecdysone, in human breast adenocarcinoma MCF-7 cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Breast Neoplasms / metabolism. Leuzea / chemistry. Plant Extracts / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975255.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


56. Thornburg JM, Nelson KK, Clem BF, Lane AN, Arumugam S, Simmons A, Eaton JW, Telang S, Chesney J: Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res; 2008;10(5):R84
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting aspartate aminotransferase in breast cancer.
  • INTRODUCTION: Glycolysis is increased in breast adenocarcinoma cells relative to adjacent normal cells in order to produce the ATP and anabolic precursors required for survival, growth and invasion.
  • Lactate dehydrogenase (LDH) regulates glycolytic flux by converting pyruvate to lactate and has been found to be highly expressed in breast tumours.
  • Oxamate is an inhibitor of both LDH and AAT, and we hypothesised that oxamate may disrupt the metabolism and growth of breast adenocarcinoma cells.
  • We then determined the effects of oxamate and AOA on normal human mammary epithelial cells and MDA-MB-231 breast adenocarcinoma cell proliferation, and on the growth of MDA-MB-231 cells as tumours in athymic BALB/c female mice.
  • Oxamate and AOA also selectively suppressed the proliferation of MDA-MB-231 cells relative to normal human mammary epithelial cells and decreased the growth of MDA-MB-231 breast tumours in athymic mice.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6178-83 [11085542.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1688-95 [11104567.001]
  • [Cites] J Nucl Med. 2001 Jan;42(1):9-16 [11197987.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6967-72 [12011455.001]
  • [Cites] J Vet Med Sci. 2002 Nov;64(11):1065-7 [12499697.001]
  • [Cites] Breast Cancer Res. 2004;6(4):R450-9 [15217513.001]
  • [Cites] Enzyme. 1972;13(4):170-6 [4650384.001]
  • [Cites] Arch Biochem Biophys. 1973 Oct;158(2):763-81 [4782532.001]
  • [Cites] Science. 1975 Jul 11;189(4197):102-14 [1138367.001]
  • [Cites] Cancer. 1976 Apr;37(4):1825-30 [177177.001]
  • [Cites] Cancer Res. 1976 Apr;36(4):1392-6 [177206.001]
  • [Cites] Dokl Akad Nauk SSSR. 1977 Jul-Aug;235(1):212-5 [583666.001]
  • [Cites] Endokrinologie. 1978 Feb;71(1):1-12 [639760.001]
  • [Cites] J Mol Biol. 1978 Nov 5;125(3):275-92 [731696.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 1):2195-9 [221103.001]
  • [Cites] Clin Chem. 1979 Apr;25(4):555-9 [466765.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 May;77(5):2559-63 [6930651.001]
  • [Cites] J Neurochem. 1982 Oct;39(4):954-60 [6126524.001]
  • [Cites] J Neurochem. 1983 Nov;41(5):1370-83 [6619872.001]
  • [Cites] Cancer Res. 1983 Dec;43(12 Pt 1):5895-901 [6640538.001]
  • [Cites] Prog Clin Biol Res. 1984;144B:171-93 [6425857.001]
  • [Cites] Mol Biol (Mosk). 1985 Jan-Feb;19(1):196-208 [3982408.001]
  • [Cites] Cancer Res. 1986 Nov;46(11):5589-91 [3756905.001]
  • [Cites] Cancer Treat Rep. 1987 Mar;71(3):297-304 [3815395.001]
  • [Cites] Int J Cancer. 1988 Jan 15;41(1):10-6 [2826342.001]
  • [Cites] J Pathol. 1988 Oct;156(2):147-53 [3058913.001]
  • [Cites] Cancer. 1989 May 15;63(10):2008-13 [2467732.001]
  • [Cites] Biochemistry. 1989 Oct 3;28(20):8161-7 [2513875.001]
  • [Cites] J Biochem. 1990 Aug;108(2):175-84 [2121725.001]
  • [Cites] Breast Cancer Res Treat. 1991 Jan-Feb;17(3):161-9 [2039838.001]
  • [Cites] J Mol Biol. 1994 Jun 3;239(2):285-305 [8196059.001]
  • [Cites] J Biol Chem. 1994 Sep 23;269(38):23757-63 [8089148.001]
  • [Cites] J Biochem. 1994 Jul;116(1):95-107 [7798192.001]
  • [Cites] Protein Sci. 1998 Jun;7(6):1380-7 [9655342.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):609-12 [9792821.001]
  • [Cites] J Biol Chem. 1961 Feb;236:285-8 [13732587.001]
  • [Cites] J Biol Chem. 1965 Jul;240:2786-90 [14342295.001]
  • [Cites] J Biol Chem. 1965 Jul;240:2791-6 [14342296.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 27;331(1):139-46 [15845370.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):5992-7 [15840712.001]
  • [Cites] Biochem Pharmacol. 2006 Feb 14;71(4):399-407 [16368075.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7225-34 [16715124.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4182-9 [17483329.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11284-90 [18056454.001]
  • [Cites] J Biol Chem. 2008 Jan 18;283(3):1456-62 [18029352.001]
  • (PMID = 18922152.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116428; United States / NCI NIH HHS / CA / 1 R01 CA116428-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytostatic Agents; 0 / Isoenzymes; 0 / Neoplasm Proteins; 0 / RNA, Small Interfering; 0 / Recombinant Fusion Proteins; 14I68GI3OQ / Aminooxyacetic Acid; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.1.1.27.- / lactate dehydrogenase 5; EC 2.6.1.1 / Aspartate Aminotransferases; QU60N5OPLG / Oxamic Acid
  • [Other-IDs] NLM/ PMC2614520
  •  go-up   go-down


57. Aghi M, Kiehl TR, Brisman JL: Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature. J Neurooncol; 2005 Nov;75(2):149-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast adenocarcinoma metastatic to epidural cervical spine meningioma: case report and review of the literature.
  • We report a case of breast carcinoma metastatic to an epidural cervical meningioma, summarize the literature on metastases to central nervous system meningiomas, and suggest a possible mechanism.
  • Because of concern that the fracture and epidural lesion might represent metastases, we performed a metastatic work-up, which revealed a right breast mass.
  • Intraoperative frozen section revealed mixed meningioma and breast adenocarcinoma.
  • Mechanisms of this unusual process likely include meningiomas' vascularity, meningiomas' slow growth providing nutrient availability, and perhaps, as suggested by our analysis, E-cadherin expression by both meningiomas and breast cancer.
  • Metastasis to meningioma must be considered in an epidural spinal lesion in all patients with a known malignancy, with surgical aggressiveness tailored to the intraoperative pathologic diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Breast Neoplasms / pathology. Cervical Vertebrae / pathology. Meningioma / diagnosis. Meningioma / secondary. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / secondary


58. Wang CC, Chiang YM, Kuo PL, Chang JK, Hsu YL: Norsolorinic acid from Aspergillus nidulans inhibits the proliferation of human breast adenocarcinoma MCF-7 cells via Fas-mediated pathway. Basic Clin Pharmacol Toxicol; 2008 Jun;102(6):491-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Norsolorinic acid from Aspergillus nidulans inhibits the proliferation of human breast adenocarcinoma MCF-7 cells via Fas-mediated pathway.
  • Norsolorinic acid, isolated from the Aspergillus nidulans, was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1998 Sep 10;8(18):1001-8 [9740801.001]
  • [Cites] Leukemia. 1998 Nov;12(11):1756-63 [9823951.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):953-61 [10029090.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17612-8 [10364198.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4392-9 [10485488.001]
  • [Cites] J Surg Res. 2005 Feb;123(2):302-11 [15680394.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):333-44 [15626723.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):195-201 [12462380.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2611-20 [12730675.001]
  • [Cites] Oncogene. 2003 Oct 9;22(44):6883-90 [14534535.001]
  • [Cites] Oncogene. 2004 Jan 8;23(1):21-9 [14712207.001]
  • [Cites] Breast Cancer Res. 2004;6(3):R180-6 [15084241.001]
  • [Cites] Biochem Pharmacol. 2004 Mar 1;67(5):823-9 [15104235.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1988 Feb;36(2):670-5 [3409376.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):707-10 [8259216.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1169-78 [7505205.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1013-23 [8137420.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3391-5 [8012956.001]
  • [Cites] Breast Cancer Res Treat. 1994 Jan;29(1):127-38 [8018961.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Genes Dev. 1995 Apr 15;9(8):935-44 [7774811.001]
  • [Cites] Adv Space Res. 1994;14(10):115-20 [11538024.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1777-83 [7500022.001]
  • [Cites] Nucleic Acids Res. 1997 Feb 1;25(3):680-1 [9016614.001]
  • [Cites] Blood. 1997 Mar 15;89(6):1854-61 [9058704.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7406-20 [17671211.001]
  • [Cites] Cancer Lett. 2005 Jun 8;223(2):293-301 [15896464.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):37-47; quiz 50-1 [16449185.001]
  • [Cites] Med J Aust. 2006 Mar 6;184(5):230-4 [16515434.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jul;59(1):1-14 [16600619.001]
  • [Cites] Oncogene. 1999 Nov 1;18(45):6145-57 [10557106.001]
  • [Cites] Oncogene. 1999 Dec 13;18(53):7621-36 [10618702.001]
  • [Cites] J Cell Physiol. 2000 Feb;182(2):171-81 [10623880.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):822-8 [10706087.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):327-32 [11196181.001]
  • [Cites] Nature. 2001 May 17;411(6835):342-8 [11357141.001]
  • [Cites] Br J Pharmacol. 2002 Jan;135(1):79-86 [11786482.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):31-43 [11925103.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Cell. 2002 Jul 12;110(1):9-12 [12150992.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7901-11 [12420228.001]
  • (PMID = 18346044.001).
  • [ISSN] 1742-7843
  • [Journal-full-title] Basic & clinical pharmacology & toxicology
  • [ISO-abbreviation] Basic Clin. Pharmacol. Toxicol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM075857; United States / NIGMS NIH HHS / GM / GM075857
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Fas Ligand Protein; 0 / Plant Extracts; 78371-59-2 / norsolorinic acid
  • [Other-IDs] NLM/ NIHMS492744; NLM/ PMC3754440
  •  go-up   go-down


59. Chen T, Wong YS: Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation. J Agric Food Chem; 2008 Nov 26;56(22):10574-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selenocystine induces S-phase arrest and apoptosis in human breast adenocarcinoma MCF-7 cells by modulating ERK and Akt phosphorylation.
  • The present study shows that SeC inhibited the proliferation of human breast adenocarcinoma MCF-7 cells in a time- and dose-dependent manner, through the induction of cell cycle arrest and apoptotic cell death.
  • [MeSH-minor] Adenocarcinoma. Breast Neoplasms. Cell Division / drug effects. Cell Line, Tumor. Humans. Mitogen-Activated Protein Kinases / metabolism. Phosphorylation / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18959417.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 1464-43-3 / selenocystine; 48TCX9A1VT / Cystine; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


60. Ravizza R, Gariboldi MB, Molteni R, Monti E: Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells. Oncol Rep; 2008 Sep;20(3):625-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linalool, a plant-derived monoterpene alcohol, reverses doxorubicin resistance in human breast adenocarcinoma cells.
  • In the present study, the effects of linalool (LIN), a monoterpene alcohol found in the essential oils from many aromatic plants, on the growth of two human breast adenocarcinoma cell lines, MCF7 WT and multidrug resistant MCF7 AdrR, were investigated, both as a single agent and in combination with doxorubicin (DOX).
  • In summary, the results of the present study suggest that LIN may improve the therapeutic index of anthracyclines in the management of breast cancer, especially in MDR tumors.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Breast Neoplasms / drug therapy. Doxorubicin / adverse effects. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. Insecticides / therapeutic use. Monoterpenes / therapeutic use. Protective Agents / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Apoptosis / drug effects. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Inhibitor of Apoptosis Proteins. Inhibitory Concentration 50. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Cells, Cultured / drug effects. Tumor Suppressor Protein p53 / metabolism. bcl-2-Associated X Protein / metabolism. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. LINALOOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695915.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / BIRC5 protein, human; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Inhibitor of Apoptosis Proteins; 0 / Insecticides; 0 / Microtubule-Associated Proteins; 0 / Monoterpenes; 0 / Neoplasm Proteins; 0 / Protective Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein; 80168379AG / Doxorubicin; D81QY6I88E / linalool
  •  go-up   go-down


61. Shadidi M, Sørensen D, Dybwad A, Furset G, Sioud M: Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma. Int J Oncol; 2008 Jan;32(1):241-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosal vaccination with phage-displayed tumour antigens identified through proteomics-based strategy inhibits the growth and metastasis of 4T1 breast adenocarcinoma.
  • Here, we used a proteomics-based approach to identify tumour antigens recognized by serum antibodies from patients with breast cancer.
  • Furthermore, these immune responses inhibited tumour growth and metastasis of the 4T1 mammary adenocarcinoma cell line.
  • [MeSH-major] Adenocarcinoma / therapy. Antigens, Neoplasm / immunology. Cancer Vaccines / immunology. Mammary Neoplasms, Experimental / therapy. Peptide Library. Proteomics. Vaccines, Synthetic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097564.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Peptide Library; 0 / Vaccines, Synthetic
  •  go-up   go-down


62. Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d'Arcy JA, Collins DJ, Padhani AR: Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology; 2010 Dec;257(3):643-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
  • PURPOSE: To investigate the histopathologic and dynamic magnetic resonance (MR) imaging correlates of intrinsic susceptibility-weighted (ISW) MR imaging in patients with primary human breast adenocarcinoma and to assess the relationship between baseline transverse relaxation rate (R2*) and T2* relaxivity change (ΔR2*) and the response to neoadjuvant chemotherapy (NAC).
  • Between September 2001 and January 2008, 83 women (median age, 46 years; age range, 26-72 years) with breast cancer were recruited to undergo dynamic contrast medium-enhanced (DCE), dynamic susceptibility contrast-enhanced (DSC), and ISW MR imaging before and after two cycles of NAC.
  • Baseline adenocarcinoma R2* (n = 31) and ΔR2* (n = 27) were correlated with final pathologic response.
  • Baseline R2* values were lower in tumors than in normal breast tissue (31.8 sec(-1) vs 36.2 sec(-1), P = .017) but not after NAC.
  • CONCLUSION: R2* is influenced by blood volume in untreated breast adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © RSNA, 2010
  • (PMID = 20858850.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Taxoids; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil
  •  go-up   go-down


63. Linares Torres P, Castañón López C, Llano Alonso C, Alvarez Posadilla M, Vivas Alegre S, Espinel Díez J, Ribas Arino MT: [Association of adenocarcinoma of esophagus and breast cancer in a male with Madelung' disease]. An Med Interna; 2006 Mar;23(3):133-5
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Association of adenocarcinoma of esophagus and breast cancer in a male with Madelung' disease].
  • [Transliterated title] Asociación de adenocarcinoma de esófago y cáncer de mama en un varón con enfermedad de Madelung.
  • The development of a cancer of the esophagus in women who previously had received radiotherapy for breast cancer is a known although infrequent event.
  • We report a case of adenocarcinoma of the esophagus in a man diagnosed of benign symmetrical lipomatosis (Madelung' disease), who had received adjuvant radiotherapy three years before for breast cancer.
  • [MeSH-major] Adenocarcinoma / complications. Breast Neoplasms, Male / complications. Carcinoma, Ductal, Breast / complications. Esophageal Neoplasms / complications. Lipomatosis, Multiple Symmetrical / complications. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Radiotherapy, Adjuvant / adverse effects


64. Barz M, Luxenhofer R, Zentel R, Kabanov AV: The uptake of N-(2-hydroxypropyl)-methacrylamide based homo, random and block copolymers by human multi-drug resistant breast adenocarcinoma cells. Biomaterials; 2009 Oct;30(29):5682-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The uptake of N-(2-hydroxypropyl)-methacrylamide based homo, random and block copolymers by human multi-drug resistant breast adenocarcinoma cells.
  • The cellular uptake of these polymers was investigated in the human multi-drug resistant breast adenocarcinoma cell line MCF7/ADR.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] J Cell Biol. 1982 May;93(2):269-77 [6178742.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):169-85 [11259839.001]
  • [Cites] PDA J Pharm Sci Technol. 2001 May-Jun;55(3):191-201 [11417110.001]
  • [Cites] J Control Release. 2002 Aug 21;82(2-3):189-212 [12175737.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):845-54 [12538842.001]
  • [Cites] Nat Rev Drug Discov. 2003 Mar;2(3):214-21 [12612647.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] Clin Pharmacokinet. 2003;42(13):1089-105 [14531722.001]
  • [Cites] Angew Chem Int Ed Engl. 1972 Dec;11(12):1103-4 [4630476.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Jun 27;44(26):4061-6 [15912547.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Feb 13;45(8):1198-215 [16444775.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Chem Rev. 2007 Jun;107(6):2270-99 [17530906.001]
  • [Cites] Nat Mater. 2008 Jul;7(7):588-95 [18500347.001]
  • [Cites] Nat Nanotechnol. 2008 Mar;3(3):145-50 [18654486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11613-8 [18697944.001]
  • [Cites] Bioconjug Chem. 2008 Oct;19(10):2023-9 [18729494.001]
  • [Cites] Biomacromolecules. 2008 Nov;9(11):3114-8 [18855476.001]
  • [Cites] Pharm Res. 2008 Dec;25(12):2845-52 [18592353.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(29):5309-12 [19294716.001]
  • [Cites] Biomacromolecules. 2009 Jul 13;10(7):1697-703 [19425549.001]
  • [Cites] Eur J Pharm Biopharm. 2000 Jul;50(1):61-81 [10840193.001]
  • (PMID = 19631373.001).
  • [ISSN] 1878-5905
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA089225-09; United States / NCI NIH HHS / CA / R01 CA089225; United States / NCI NIH HHS / CA / 2R01 CA89225; United States / NCI NIH HHS / CA / R01 CA089225-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Acrylamides; 0 / Drug Carriers; 0 / Polymers; 21442-01-3 / N-(2-hydroxypropyl)methacrylamide
  • [Other-IDs] NLM/ NIHMS290104; NLM/ PMC3089424
  •  go-up   go-down


65. Murphy JP, Pinto DM: Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells. Proteomics; 2010 May;10(9):1847-60
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal proteomic analysis of IGF-1R signalling in MCF-7 breast adenocarcinoma cells.
  • We explored proteomic changes resulting from insulin-like growth factor 1 stimulation of MCF-7 adenocarcinoma cells as a function of time.
  • [MeSH-major] Adenocarcinoma / chemistry. Breast Neoplasms / chemistry. Receptor, IGF Type 1 / metabolism. Signal Transduction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213678.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


66. Gibson GR, Qian D, Ku JK, Lai LL: Metaplastic breast cancer: clinical features and outcomes. Am Surg; 2005 Sep;71(9):725-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic breast cancer: clinical features and outcomes.
  • Metaplastic carcinoma of the breast, a neoplasm with both epithelial and mesenchymal elements, represents less than 1 per cent of all breast cancer.
  • We reviewed the records of all patients diagnosed with localized metaplastic breast cancer from 1991 to 2003 at our institution.
  • Metaplastic breast cancer is a unique neoplasm that tends to present at an advanced stage and has a propensity for local recurrence.
  • When stratified by stage, however, survival appears similar to that of adenocarcinoma of the breast, and these tumors should be treated as such.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Breast Neoplasms / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468506.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


67. Karamouzis MV, Ardavanis A, Alexopoulos A, Papadopoulou A, Apostolikas N, Rigatos G: Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association? Eur J Cancer Care (Engl); 2005 Jul;14(3):267-71
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
  • This paper reports the case of a 45-year-old female with histologically documented, multiple cutaneous metastases in the palmar and plantar surface of the fingers and toes originating from a breast adenocarcinoma after treatment with a docetaxel and pegylated liposomal doxorubicin regimen.
  • The rarity of such a metastatic pattern from breast cancer and the eventual association with the chemotherapy administered are thoroughly discussed.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Doxorubicin / administration & dosage. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952972.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Liposomes; 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin
  •  go-up   go-down


68. Carvalho S, Branco R, Serralheiro P, Saraiva T, Carvalho L: [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University]. Rev Port Pneumol; 2006 May-Jun;12(3):255-68
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung adenocarcinoma: application of the WHO 1999/2004 classification to the caseload of the Pathologic Anatomy Service at the Hospital of the Coimbra University].
  • [Transliterated title] Adenocarcinoma do pulmão: Aplicação da classificação WHO 1999/2004 à casuística do Serviço de Anatomia Patológica do Hospital da Universidade de Coimbra.
  • A study of 701 primary adenocarcinomas of the lung was made at the Department of Pathology of the Hospital da Universidade de Coimbra for a period of fifteen years, between 1990 and 2004.
  • In the same period 382 metastases were diagnosed, mainly from colon (119) and breast (66).
  • In the last four years, since 2001, patients were in the seventies at the time of diagnosis and a considerable number of cases were diagnosed after 80 years of age.
  • A number of 109 cases had the final diagnosis of adenocarcinoma of the lung based on morphology and immunohistochemistry criteria.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. International Classification of Diseases. Lung Neoplasms / classification. Lung Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967175.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


69. Maimon Y, Karaush V, Yaal-Hahoshen N, Ben-Yosef R, Ron I, Vexler A, Lev-Ari S: Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J Int Med Res; 2010;38(6):2033-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines.
  • The aim of this study was to assess the effect of a unique Chinese herbal therapy (CHT) from controlled manufactured concentrated powders, on an in vitro model of breast cancer.
  • Three breast adenocarcinoma cell lines (MDA-231, MDA-453, T47D) were exposed to CHT for 72 h.
  • A randomized clinical trial is currently underway to investigate CHT as supplementary therapy for breast cancer patients receiving chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Breast Neoplasms / drug therapy. Drugs, Chinese Herbal / therapeutic use. Phytotherapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21227007.001).
  • [ISSN] 1473-2300
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


70. Vorster C, Joubert A: In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line. Biocell; 2010 Aug;34(2):71-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line.
  • The objective of this study was to evaluate 2ME-BM's in vitro efficacy as antiproliferative agent in the MCF-7 breast adenocarcinoma cell line.
  • [MeSH-minor] Breast Neoplasms. Cell Cycle / drug effects. Cell Proliferation / drug effects. Cell Shape / drug effects. Female. Humans. Molecular Structure

  • Hazardous Substances Data Bank. ESTRIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925196.001).
  • [ISSN] 0327-9545
  • [Journal-full-title] Biocell : official journal of the Sociedades Latinoamericanas de Microscopía Electronica ... et. al
  • [ISO-abbreviation] Biocell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Argentina
  • [Chemical-registry-number] 1236-72-2 / 2-methoxyestriol; FB33469R8E / Estriol
  •  go-up   go-down


71. Tiang JM, Butcher NJ, Minchin RF: Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun; 2010 Feb 26;393(1):95-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small molecule inhibition of arylamine N-acetyltransferase Type I inhibits proliferation and invasiveness of MDA-MB-231 breast cancer cells.
  • Arylamine N-acetyltransferase 1 is a phase II metabolizing enzyme that has been associated with certain breast cancer subtypes.
  • While it has been linked to breast cancer risk because of its role in the metabolic activation and detoxification of carcinogens, recent studies have suggested it may be important in cell growth and survival.
  • To address the possible importance of NAT1 in breast cancer, we have used a novel small molecule inhibitor (Rhod-o-hp) of the enzyme to examine growth and invasion of the breast adenocarcinoma line MDA-MB-231.
  • Taken together, the results of this study demonstrate that NAT1 activity may be important in breast cancer growth and metastasis.
  • The study suggests that NAT1 is a novel target for breast cancer treatment.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Arylamine N-Acetyltransferase / metabolism. Breast Neoplasms / enzymology. Breast Neoplasms / pathology. Isoenzymes / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. RHODANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20100460.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (Z)-5-(2'-hydroxybenzylidene)-2-thioxothiazolidin-4-one; 0 / Enzyme Inhibitors; 0 / Isoenzymes; 7O50LKL2G8 / Rhodanine; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1
  •  go-up   go-down


72. Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C, Dugan U, Heimbrook D, Packman K: Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res; 2007 Jul-Aug;27(4B):2279-87
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
  • Their combination failed to improve survival in a phase III trial of metastatic breast cancer (MBC), although it should be noted patients had been heavily pretreated with anthracyclines and taxanes.
  • Our aim was to evaluate whether combination treatment would increase tumor growth inhibition and survival in a breast cancer model.
  • MATERIALS AND METHODS: Mice bearing KPL-4 human estrogen receptor-negative breast adenocarcinoma xenografts were given capecitabine orally daily for 14 days at the maximum tolerated dose (MTD) or half MTD, alone or with 5 mg/kg intraperitoneal bevacizumab twice weekly.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Breast Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695515.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Receptors, Estrogen; 0W860991D6 / Deoxycytidine; 2S9ZZM9Q9V / Bevacizumab; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Ewens A, Mihich E, Ehrke MJ: Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma. Anticancer Res; 2005 Nov-Dec;25(6B):3905-15
Cellosaurus - a cell line knowledge resource. culture/stock collections - E0771 (CVCL_GR23) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distant metastasis from subcutaneously grown E0771 medullary breast adenocarcinoma.
  • BACKGROUND: Breast cancer treatments are most effective when initiated early, with very poor efficacy against metastatic disease.
  • In seeking a readily metastasizing mouse breast cancer model to facilitate the search for effective therapies, E0771 medullary adenocarcinomas implanted subcutaneously in syngeneic C57BL/6 mice were studied.
  • CONCLUSION: The E0771 metastatic breast cancer model, which mimics the human disease, should be useful in testing new treatments against this disease and/or in examining the metastatic process.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16312045.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16056; United States / NCI NIH HHS / CA / R0-1 CA15142
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  •  go-up   go-down


74. Hsu YL, Uen YH, Chen Y, Liang HL, Kuo PL: Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis. J Agric Food Chem; 2009 Sep 23;57(18):8688-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tricetin, a dietary flavonoid, inhibits proliferation of human breast adenocarcinoma mcf-7 cells by blocking cell cycle progression and inducing apoptosis.
  • This study is the first to investigate the anticancer effect of tricetin in human breast adenocarcinoma MCF-7 cells.
  • These findings suggest that tricetin may be a promising chemopreventive agent against human breast cancer.
  • [MeSH-major] Apoptosis / drug effects. Breast Neoplasms / pathology. Cell Cycle / drug effects. Cell Division / drug effects. Chromones / pharmacology
  • [MeSH-minor] Adenocarcinoma / pathology. Anticarcinogenic Agents. Caspase 9 / metabolism. Caspase Inhibitors. Cell Line, Tumor. G2 Phase / drug effects. Humans. In Situ Nick-End Labeling

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19705844.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Caspase Inhibitors; 0 / Chromones; 520-31-0 / tricetin; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


75. Kuo PL, Cho CY, Hsu YL, Lin TC, Lin CC: Putranjivain A from Euphorbia jolkini inhibits proliferation of human breast adenocarcinoma MCF-7 cells via blocking cell cycle progression and inducing apoptosis. Toxicol Appl Pharmacol; 2006 May 15;213(1):37-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Putranjivain A from Euphorbia jolkini inhibits proliferation of human breast adenocarcinoma MCF-7 cells via blocking cell cycle progression and inducing apoptosis.
  • Putranjivain A, isolated from the whole plant of Euphorbia jolkini Bioss (Euphorbiaceae), was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells.
  • [MeSH-minor] Adenocarcinoma. Antigens, CD95 / biosynthesis. Breast Neoplasms. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / biosynthesis. Fas Ligand Protein. Female. Humans. Membrane Glycoproteins / biosynthesis. Tumor Necrosis Factors / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • Hazardous Substances Data Bank. GALLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171837.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antineoplastic Agents, Phytogenic; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Glucosides; 0 / Membrane Glycoproteins; 0 / Tumor Necrosis Factors; 0 / Tumor Suppressor Protein p53; 0 / putranjivain A; 632XD903SP / Gallic Acid
  •  go-up   go-down


76. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther; 2007 Mar;6(3):1089-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets.
  • In the present study, we examined the alterations in epigenetic mechanisms in the drug-resistant MCF-7 human breast cancer cells induced by doxorubicin (DOX) and cisplatin (cisDDP), two chemotherapeutic drugs with different modes of action.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. DNA Methylation / drug effects. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm. Epigenesis, Genetic

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363502.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Histones; 80168379AG / Doxorubicin; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.- / histone methyltransferase; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Rapkiewicz A, Espina V, Zujewski JA, Lebowitz PF, Filie A, Wulfkuhle J, Camphausen K, Petricoin EF 3rd, Liotta LA, Abati A: The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer; 2007 Jun 25;111(3):173-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology.
  • Reverse-phase protein microarray (RPPM) technology has been applied successfully to the quantitative analysis of breast, ovarian, prostate, and colorectal cancers using frozen surgical specimens.
  • RPPMs were printed with 63 breast FNA samples that were obtained before, during, and after treatment from 21 patients who were enrolled in a Phase II trial of neoadjuvant capecitabine and docetaxel therapy for breast cancer.
  • RESULTS: Based on an MCF7 cell line model of breast adenocarcinoma, the sensitivity of the RPPM detection method was in the femtomolar range with a coefficient of variance <13.5% for the most dilute sample.
  • [MeSH-major] Breast Neoplasms / metabolism. Microarray Analysis / methods. Proteome / analysis. Proteomics / methods
  • [MeSH-minor] Bayes Theorem. Biopsy, Fine-Needle / methods. Breast / metabolism. Breast / pathology. Cell Line, Tumor. Cluster Analysis. Female. Humans. Phosphoproteins / analysis. Protein Kinases / analysis. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487852.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphoproteins; 0 / Proteome; EC 2.7.- / Protein Kinases
  •  go-up   go-down


78. Kuo PL, Hsu YL, Sung SC, Ni WC, Lin TC, Lin CC: Induction of apoptosis in human breast adenocarcinoma MCF-7 cells by pterocarnin A from the bark of Pterocarya stenoptera via the Fas-mediated pathway. Anticancer Drugs; 2007 Jun;18(5):555-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in human breast adenocarcinoma MCF-7 cells by pterocarnin A from the bark of Pterocarya stenoptera via the Fas-mediated pathway.
  • Pterocarnin A, isolated from the bark of Pterocarya stenoptera (Juylandaceae), was investigated for its antiproliferative activity in human breast adenocarcinoma MCF-7 cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Breast Neoplasms / drug therapy. Fas Ligand Protein / physiology. Gallic Acid / analogs & derivatives. Glycosides / pharmacology. Juglandaceae / chemistry

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GALLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414624.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Fas Ligand Protein; 0 / Glycosides; 0 / pterocarnin A; 632XD903SP / Gallic Acid; EC 3.4.22.- / Caspase 8; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


79. Kirkpatrick JP, Hardee ME, Snyder SA, Peltz CM, Zhao Y, Brizel DM, Dewhirst MW, Blackwell KL: The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res; 2006 Feb;165(2):192-201
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma.
  • Tumor hypoxia is associated with poor clinical outcome in a variety of tumors, including cervical, head/neck and breast cancer.
  • This study randomized rats to treatment with low-dose or high-dose darbepoetin alfa or a placebo to determine the effect of darbepoetin alfa on the pO2, growth and response to radiation therapy of R3230 mammary adenocarcinoma.
  • In this nonanemic animal model of mammary adenocarcinoma, darbepoetin alfa does not significantly alter tumor growth or radioresponsiveness, even though it improves oxygenation when administered at high doses.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Erythropoietin / analogs & derivatives. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / therapy. Oxygen / metabolism. Radiation Tolerance / drug effects. Radiation-Sensitizing Agents / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518899.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA40355
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 11096-26-7 / Erythropoietin; 15UQ94PT4P / Darbepoetin alfa; S88TT14065 / Oxygen
  •  go-up   go-down


80. Bui-Xuan NH, Tang PM, Wong CK, Fung KP: Photo-activated pheophorbide-a, an active component of Scutellaria barbata, enhances apoptosis via the suppression of ERK-mediated autophagy in the estrogen receptor-negative human breast adenocarcinoma cells MDA-MB-231. J Ethnopharmacol; 2010 Aug 19;131(1):95-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photo-activated pheophorbide-a, an active component of Scutellaria barbata, enhances apoptosis via the suppression of ERK-mediated autophagy in the estrogen receptor-negative human breast adenocarcinoma cells MDA-MB-231.
  • However, the effectiveness of Pa-PDT has not yet been evaluated on human breast cancer, which is documented as the second common and the fifth most lethal cancer worldwide.
  • MATERIALS AND METHODS: The cytotoxicity of Pa-PDT was evaluated by using an estrogen receptor (ER)-negative human breast adenocarcinoma cell line MDA-MB-231.
  • CONCLUSION: The present study suggested Pa-PDT is a potential protocol for the late phase human breast cancer, and it is the first study to demonstrate the Pa-PDT induced autophagy contributed to the anti-tumor effects of Pa-PDT on human cancer cells.
  • [MeSH-major] Adenocarcinoma. Breast Neoplasms. Chlorophyll / analogs & derivatives. Extracellular Signal-Regulated MAP Kinases / antagonists & inhibitors. Plant Extracts / pharmacology. Receptors, Estrogen / deficiency. Scutellaria

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ireland Ltd.
  • (PMID = 20558270.001).
  • [ISSN] 1872-7573
  • [Journal-full-title] Journal of ethnopharmacology
  • [ISO-abbreviation] J Ethnopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Protein Kinase Inhibitors; 0 / Radiation-Sensitizing Agents; 0 / Receptors, Estrogen; 0 / Scutellaria barbata extract; 1406-65-1 / Chlorophyll; 15664-29-6 / pheophorbide a; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


81. Tomita A, Kasaoka T, Inui T, Toyoshima M, Nishiyama H, Saiki H, Iguchi H, Nakajima M: Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin Exp Metastasis; 2008;25(4):437-44
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.
  • In this study, we first established a reproducible in vivo bone metastasis model using two types of tumor cells, human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara cells), and examined in vitro characteristics of the tumor cells.
  • [MeSH-major] Adenocarcinoma / pathology. Bone Neoplasms / secondary. Bone Resorption / etiology. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301992.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; 0 / RNA, Messenger; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K; EC 3.4.22.38 / Ctsk protein, mouse; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


82. Soria EA, Eynard AR, Quiroga PL, Bongiovanni GA: Differential effects of quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines. Life Sci; 2007 Oct 13;81(17-18):1397-402
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential effects of quercetin and silymarin on arsenite-induced cytotoxicity in two human breast adenocarcinoma cell lines.
  • The human mammary adenocarcinoma lines MCF-7 and ZR-75-1 were treated in vitro with 200 microM NaAsO(2) (As), 5 microM silymarin (S) and/or 50 microM quercetin (Q).
  • [MeSH-minor] Breast Neoplasms. Cell Line, Tumor. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Survival / drug effects. Female. Free Radicals / metabolism. Humans. Lipid Peroxidation / drug effects. N-Acetylneuraminic Acid / metabolism. Time Factors. gamma-Glutamyltransferase / metabolism

  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931660.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arsenites; 0 / Free Radicals; 0 / Silymarin; 0 / Sodium Compounds; 48OVY2OC72 / sodium arsenite; 9IKM0I5T1E / Quercetin; EC 2.3.2.2 / gamma-Glutamyltransferase; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


83. Wiesen KM, Xia S, Yang CP, Horwitz SB: Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation. Cancer Lett; 2007 Nov 18;257(2):227-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wild-type class I beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation.
  • A Taxol-resistant cell line, K20T, which does not express P-glycoprotein, was selected with Taxol from human MDA-MB-231 breast adenocarcinoma cells and maintained in the presence of 20nM Taxol.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Alkanes / pharmacology. Antineoplastic Agents, Phytogenic / pharmacology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carbamates / pharmacology. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / genetics. Dimerization. Epothilones / pharmacology. Fluorescent Antibody Technique, Indirect. Glutamic Acid / genetics. Glycine / genetics. Humans. Lactones / pharmacology. Models, Molecular. Protein Structure, Quaternary. Pyrones / pharmacology. Taxoids / pharmacology. Transfection. Tubulin Modulators / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. GLYCINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869412.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2T32-CA09475-11; United States / NCI NIH HHS / CA / CA083185
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Alkanes; 0 / Antineoplastic Agents, Phytogenic; 0 / Carbamates; 0 / Epothilones; 0 / Lactones; 0 / Pyrones; 0 / Taxoids; 0 / Tubulin; 0 / Tubulin Modulators; 15H5577CQD / docetaxel; 3KX376GY7L / Glutamic Acid; DHG59994DN / discodermolide; P88XT4IS4D / Paclitaxel; TE7660XO1C / Glycine
  •  go-up   go-down


84. Lee YB, Ko KC, Shi MD, Liao YC, Chiang TA, Wu PF, Shih YX, Shih YW: alpha-Mangostin, a novel dietary xanthone, suppresses TPA-mediated MMP-2 and MMP-9 expressions through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells. J Food Sci; 2010 Jan-Feb;75(1):H13-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] alpha-Mangostin, a novel dietary xanthone, suppresses TPA-mediated MMP-2 and MMP-9 expressions through the ERK signaling pathway in MCF-7 human breast adenocarcinoma cells.
  • This study first investigates the anti-metastatic effect of alpha-mangostin on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) expressions in human breast adenocarcinoma cells, MCF-7.
  • [MeSH-major] Adenocarcinoma / enzymology. Breast Neoplasms / enzymology. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 9 / genetics. Mitogen-Activated Protein Kinase 3 / metabolism. Tetradecanoylphorbol Acetate / pharmacology. Xanthones / pharmacology


85. Martins FC, Botelho MF, Cabrita AM, de Oliveira CF: Influence of normal mammary epithelium on breast cancer progression: the protective role of early pregnancy. Tumori; 2010 Nov-Dec;96(6):999-1003
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of normal mammary epithelium on breast cancer progression: the protective role of early pregnancy.
  • AIMS AND BACKGROUND: The microenvironment has a well recognized role in breast cancer progression.
  • Since pregnancy is responsible for mammary gland differentiation, we tested the hypothesis that differentiated mammary epithelial cells may inhibit breast cancer progression.
  • METHODS: In order to test our hypothesis, we used 30 female Balb/c nude mice and MCF-7 cells of breast adenocarcinoma.
  • [MeSH-major] Breast / growth & development. Cell Transformation, Neoplastic / pathology. Epithelial Cells / pathology. Mammary Glands, Animal / pathology. Mammary Neoplasms, Experimental / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21388065.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


86. Brevet M, Haren N, Sevestre H, Merviel P, Ouadid-Ahidouch H: DNA methylation of K(v)1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma. Cell Physiol Biochem; 2009;24(1-2):25-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA methylation of K(v)1.3 potassium channel gene promoter is associated with poorly differentiated breast adenocarcinoma.
  • BACKGROUND: DNA methylation is an important mechanism for gene silencing and has already been described for several genes in breast cancer.
  • A previous immunohistochemistry study demonstrated a decrease of K(v)1.3 potassium channel expression in breast adenocarcinoma compared to normal breast tissue.
  • METHODS: Methyl-specific PCR (MSP), immunohistochemistry and RNA extraction were performed on breast adenocarcinoma.
  • MSP and DNA extraction were also performed on one breast carcinoma cell line and on primary culture normal cells.
  • Finally, K(v)1.3 gene promoter was methylated in the MCF-7 breast carcinoma cell line while promoter methylation was absent in primary culture of normal breast cells (HMEpC).
  • CONCLUSION: We report, for the first time, the methylation of the K(v)1.3 gene promoter in breast adenocarcinoma.
  • Our data suggest that DNA methylation is responsible for a decrease of K(v)1.3 gene expression in breast adenocarcinoma and is associated with poorly differentiated tumors and younger patients.
  • [MeSH-major] Adenocarcinoma / genetics. Breast Neoplasms / genetics. DNA Methylation. Kv1.3 Potassium Channel / genetics. Promoter Regions, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 19590190.001).
  • [ISSN] 1421-9778
  • [Journal-full-title] Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  • [ISO-abbreviation] Cell. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Kv1.3 Potassium Channel; 0 / RNA, Messenger
  •  go-up   go-down


87. Farhat F, Fakhruddine N: A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman. Eur J Gynaecol Oncol; 2008;29(1):95-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman.
  • PURPOSE & METHODS: We report a case of a 42-year-old multigravida, premenopausal woman with breast carcinoma, who presented after four years of use of adjuvant tamoxifen with synchronous liver, bone, and lung metastasis of breast cancer with müllerian adenosarcoma.
  • CONCLUSION: Our case is the only one reported in the literature with synchronous relapse of breast adenocarcinoma and a Müllerian adenosarcoma.
  • [MeSH-major] Adenosarcoma / pathology. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / pathology. Neoplasm Recurrence, Local / complications. Tamoxifen / adverse effects. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18386476.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 12
  •  go-up   go-down


88. Baranzelli MC, Giard S, Cabaret V, Chauvet MP, Robin YM, Vilain MO, Carpentier P, Belkacémi Y, Bonneterre J: [Breast adenocarcinoma: critical analysis of sentinel lymph node histopathological results of 542 procedures]. Bull Cancer; 2005 Nov;92(11):983-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast adenocarcinoma: critical analysis of sentinel lymph node histopathological results of 542 procedures].
  • [Transliterated title] Adénocarcinomes mammaires: analyse critique des résultats histopathologiques des ganglions sentinelles, à propos de 542 cas.
  • Between February 2001 and March 2003, 542 sentinel lymph node procedures were performed for localised breast carcinoma (T0-T1, N0, M0) without any previous treatment.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16316832.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


89. Prasanna R, Harish CC: Anticancer effect of a novel 2-arylidene-4,7-dimethyl indan-1-one against human breast adenocarcinoma cell line by G2/M cell cycle arrest. Oncol Res; 2010;18(10):461-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anticancer effect of a novel 2-arylidene-4,7-dimethyl indan-1-one against human breast adenocarcinoma cell line by G2/M cell cycle arrest.
  • A novel compound 2-arylidene-4,7-dimethyl indan-1-one synthesized was screened for anticancer effect against the human breast adenocarcinoma cell line, MCF-7.
  • An IC50 value of > or = 80 microM, nontoxic to the normal breast cell line HBL-100, showed complete inhibition of the MCF-7 cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Breast Neoplasms / drug therapy. Cell Division / drug effects. G2 Phase / drug effects. Indans / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20681405.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indans; 0 / Tumor Suppressor Protein p53; GAN16C9B8O / Glutathione
  •  go-up   go-down


90. Torres Muros B, Bonilla Parrilla R, Solano Romero JR, Rodríguez Baró JG, Verge González J: [Metastasis in maxilar sinus as only manifestation of disseminate renal adenocarcinoma]. An Otorrinolaringol Ibero Am; 2007;34(3):231-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis in maxilar sinus as only manifestation of disseminate renal adenocarcinoma].
  • [Transliterated title] Metástasis en seno maxilar como única manifestación de adenocarcinoma renal diseminado.
  • Renal cell carcinoma is the primary neoplasm which most frequently metastasizes in the nasosinusal region, followed by breast and lug.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17725166.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


91. Furuta C, Suzuki AK, Watanabe G, Li C, Taneda S, Taya K: Nitrophenols isolated from diesel exhaust particles promote the growth of MCF-7 breast adenocarcinoma cells. Toxicol Appl Pharmacol; 2008 Aug 1;230(3):320-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitrophenols isolated from diesel exhaust particles promote the growth of MCF-7 breast adenocarcinoma cells.
  • Diesel exhaust particles (DEPs) cause many adverse health problems, and reports indicate increased risk of breast cancer in men and women through exposure to gasoline and vehicle exhaust.
  • Here, we tried to clarify the involvement of these two nitrophenols in promoting the growth of the MCF-7 breast cancer cell line.
  • Next, the estrogen-responsive breast cancer cell line MCF-7 was used to assess cell proliferation.
  • These results clearly indicate that PNMC and PNMPP do not show genotoxicity but act as tumor promoters in an estrogen receptor alpha-predominant breast cancer cell line.
  • [MeSH-major] Biphenyl Compounds / toxicity. Breast Neoplasms / pathology. Cresols / toxicity. Nitrophenols / toxicity. Vehicle Emissions / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18439640.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-nitro-3-phenylphenol; 0 / Biphenyl Compounds; 0 / Cresols; 0 / Nitrophenols; 0 / Receptors, Estrogen; 0 / Vehicle Emissions; 2CC94832EU / 4-nitro-3-cresol
  •  go-up   go-down


92. Pandya NK, Auerbach JD, Baldwin K, Lackman RD, Chin KR: Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report. Spine (Phila Pa 1976); 2006 Nov 15;31(24):E920-4
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine: case report.
  • SUMMARY OF BACKGROUND DATA: To our knowledge, there have been no previous reports of spinal cord compression in a patient with multiple hereditary exostoses caused by breast adenocarcinoma metastatic to osteochondromas of the spine.
  • The patient's mass was found to be breast adenocarcinoma metastatic to osteochondromas of the spine.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / diagnosis. Exostoses, Multiple Hereditary / complications. Neoplasms, Unknown Primary / diagnosis. Spinal Cord Compression / etiology. Spinal Neoplasms / secondary. Thoracic Vertebrae / surgery
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Chondrosarcoma / diagnosis. Combined Modality Therapy. Decompression, Surgical. Diagnosis, Differential. Female. Humans. Laminectomy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Paclitaxel / administration & dosage. Spinal Fusion. Tomography, X-Ray Computed. Trastuzumab


93. Fontana S, Ghilardi R, Barbaglio A, Amaddeo P, Faldi F, Pericotti S: Male breast cancer with mandibular metastasis. A case report. Minerva Stomatol; 2007 Apr;56(4):225-30
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer with mandibular metastasis. A case report.
  • Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes.
  • Influencing factors are: gynecomasty, familiarity for male breast cancer, Jewish and African-American male population.
  • From the histological point of view, it is not different from the female breast cancer, except for the infiltrant ductal carcinoma, but with a much severe prognosis.
  • Breast cancer metastases to the jaws are rare, only 1%; the most common sites of metastases are: lungs(59-69%), liver (58-65%), bone (44-71%), pleura (23-37%), brain (9-22%) and kidney (4-17%).
  • At present, based on a literature research (May 2006), there have been just two other case reports of male breast cancer metastasis to the maxillofacial region, both to the mandible.
  • The case of a 69-year-old white man who in 2001 underwent a radical mastectomy due to ductal breast cancer is reported.
  • The histological examination was consistent with that of a metastatic deposit of adenocarcinoma of the breast.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms, Male / pathology. Carcinoma, Ductal, Breast / secondary. Mandibular Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. EXEMESTANE .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Phenobarbital .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. OMEPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452960.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Taxoids; 107868-30-4 / exemestane; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 6XC1PAD3KF / zoledronic acid; 7LXU5N7ZO5 / Furosemide; 7NFE54O27T / Toremifene; 8N3DW7272P / Cyclophosphamide; KG60484QX9 / Omeprazole; Q6C979R91Y / vinorelbine; U3P01618RT / Fluorouracil; V27W9254FZ / Cortisone; YL5FZ2Y5U1 / Methotrexate; YQE403BP4D / Phenobarbital; CMF regimen
  •  go-up   go-down


94. Tham TM, Iyengar KR, Taib NA, Yip CH: Fine needle aspiration biopsy, core needle biopsy or excision biopsy to diagnose breast cancer - which is the ideal method? Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):155-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy, core needle biopsy or excision biopsy to diagnose breast cancer - which is the ideal method?
  • BACKGROUND: The ideal method for diagnosis of breast cancer is debatable.
  • METHODS: The methods of diagnosis of 436 new cases of breast adenocarcinoma presenting from Jan 2005 till Dec 2006 at the University Malaya Medical Centre (UMMC) were examined in this study.
  • RESULTS: A total of 388 cases presented to the breast unit in UMMC primarily and 48 cases were diagnosed in non-breast units in other hospitals and referred for management.
  • Fine needle aspiration cytology (FNAC) was the commonest mode of initial diagnosis in 278 cases followed by core needle biopsy and surgical excision.
  • CONCLUSION: The biopsy method used to confirm the diagnosis is influenced by where the patient first presents, and by the size of the tumour.
  • [MeSH-major] Adenofibroma / diagnosis. Biopsy / methods. Breast Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469645.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


95. Schachter HM, Mamaladze V, Lewin G, Graham ID, Brouwers M, Sampson M, Morrison A, Zhang L, O'Blenis P, Garritty C: Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review. BMC Cancer; 2006 Dec 18;6:291
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Many quality measurements, but few quality measures assessing the quality of breast cancer care in women: a systematic review.
  • BACKGROUND: Breast cancer in women is increasingly frequent, and care is complex, onerous and expensive, all of which lend urgency to improvements in care.
  • METHODS: Ten databases, including Medline, were searched electronically to identify measures assessing the quality of breast cancer care in women (diagnosis, treatment, followup, documentation of care).
  • Eligible studies measured adherence to standards of breast cancer care in women diagnosed with, or in treatment for, any histological type of adenocarcinoma of the breast.
  • RESULTS: Sixty relevant reports identified 58 studies with 143 indicators assessing adherence to quality breast cancer care.
  • ASCO's current development of a set of quality measures relating to breast cancer care may hold the key to conducting definitive studies.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Nov 27;354(9193):1896-900 [10584742.001]
  • [Cites] Health Aff (Millwood). 2004 May-Jun;23(3):89-99 [15160806.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):701-7 [10649266.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):743-53 [10673515.001]
  • [Cites] Oncol Nurs Forum. 2000 Nov-Dec;27(10):1555-64 [11103374.001]
  • [Cites] Qual Life Res. 2000;9(6):603-15 [11236851.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1676-87 [11250997.001]
  • [Cites] MedGenMed. 2001 Mar 5;3(2):2 [11549951.001]
  • [Cites] Health Aff (Millwood). 2001 May-Jun;20(3):82-90 [11585185.001]
  • [Cites] Qual Life Res. 2001;10(7):587-93 [11822792.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):459-65 [12017333.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4381-93 [12409338.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2985-91 [15284249.001]
  • [Cites] Evid Rep Technol Assess (Summ). 2004 Sep;(105):1-8 [15503541.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):191-7 [7999464.001]
  • [Cites] Ann Oncol. 1997 Sep;8(9):825-35 [9358933.001]
  • [Cites] JAMA. 1998 Sep 16;280(11):1000-5 [9749483.001]
  • [Cites] J Formos Med Assoc. 1999 Apr;98(4):254-60 [10389369.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4 Suppl 12):84-8 [10482198.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I39-47 [12544815.001]
  • [Cites] Med Care. 2003 Jan;41(1 Suppl):I48-60 [12544816.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2635-45 [12826639.001]
  • [Cites] Res Nurs Health. 1999 Dec;22(6):449-60 [10630287.001]
  • (PMID = 17176480.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 290-02-0021
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 28
  • [Other-IDs] NLM/ PMC1764760
  •  go-up   go-down


96. Madhusoodhanan R, Natarajan M, Veeraraghavan J, Herman TS, Aravindan N: NFkappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation. Cancer Biol Ther; 2009 May;8(9):765-73
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NFkappaB activity and transcriptional responses in human breast adenocarcinoma cells after single and fractionated irradiation.
  • Radiotherapy is considered mandatory for breast cancer patients undergoing conservative surgery and for women at high risk of recurrence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / radiotherapy. Breast Neoplasms / metabolism. Breast Neoplasms / radiotherapy. NF-kappa B / metabolism. Transcription, Genetic / radiation effects

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 May;8(9):774-6 [19395860.001]
  • (PMID = 19276662.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC3 protein, human; 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / NF-kappa B; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; EC 1.15.1.1 / Superoxide Dismutase; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


97. Ozer N, Deveci OS, Okutucu S, Demircin M: Asymptomatic right atrial myxoma originating from the inferior vena cava and right atrium junction in a patient with breast ductal adenocarcinoma. Turk Kardiyol Dern Ars; 2009 Oct;37(7):479-82
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic right atrial myxoma originating from the inferior vena cava and right atrium junction in a patient with breast ductal adenocarcinoma.
  • We present asymptomatic right atrial myxoma in a patient with breast ductal adenocarcinoma.
  • She had a 10-month history of modified radical mastectomy for ductal adenocarcinoma of the breast, followed by adjuvant chemotherapy.
  • The tumor was completely excised and histopathologic diagnosis was myxoma.
  • Localization of right atrial myxoma at the junction of the inferior vena cava and right atrium is a rare condition, and its coexistence with breast carcinoma has only been reported once.
  • [MeSH-major] Adenocarcinoma / complications. Breast Neoplasms / complications. Carcinoma, Ductal / complications. Heart Atria / pathology. Heart Neoplasms / complications. Myxoma / complications. Vena Cava, Inferior / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098042.001).
  • [ISSN] 1016-5169
  • [Journal-full-title] Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
  • [ISO-abbreviation] Turk Kardiyol Dern Ars
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


98. Szabo KA, Singh G: Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells. Breast Cancer Res; 2005;7(5):R661-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of monocyte matrix metalloproteinase-2 by breast adenocarcinoma cells.
  • INTRODUCTION: The presence of monocyte and macrophage cells in growing breast tumors, and the positive relationship between the degree of immune cell infiltration and tumor growth, suggest a possible paracrine growth regulatory function of immune cells in breast cancer.
  • METHOD: To better understand the interaction between monocytes and breast cancer cells, in vitro matrix metalloproteinase and tissue inhibitor of metalloproteinase activity was assessed from the THP-1 myeloid cell line in response to conditioned media from two breast cancer cell lines, MCF-7 and MDA-MB-231.
  • CONCLUSION: These data demonstrate that monocyte cells in the breast tumor microenvironment play an important role in the modulation of MMPs, which may have a significant effect on the control of tumor growth and metastatic spread.
  • [MeSH-major] Adenocarcinoma / enzymology. Breast Neoplasms / blood. Breast Neoplasms / enzymology. Macrophages / enzymology. Matrix Metalloproteinase 2 / blood. Monocytes / enzymology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1988 Feb;57(2):174-7 [2833921.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Lab Invest. 1992 Aug;67(2):166-74 [1501443.001]
  • [Cites] Immunol Today. 1992 Jul;13(7):265-70 [1388654.001]
  • [Cites] Res Immunol. 1993 May;144(4):265-8; discussion 294-8 [8378592.001]
  • [Cites] J Leukoc Biol. 1993 Oct;54(4):360-2 [8409759.001]
  • [Cites] Br J Cancer. 1993 Nov;68(5):909-15 [8217606.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):331-6 [8314319.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):410-22 [7509844.001]
  • [Cites] J Pathol. 1994 Mar;172(3):229-35 [8195926.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] J Neurooncol. 2000;46(1):81-90 [10896208.001]
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):105-15 [11097087.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Pathol Oncol Res. 2001;7(1):14-23 [11349215.001]
  • [Cites] Immunol Res. 2001;23(2-3):263-72 [11444391.001]
  • [Cites] Oncologist. 2001;6(5):415-27 [11675519.001]
  • [Cites] Clin Exp Metastasis. 2002;19(3):247-58 [12067205.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):991-8 [12407406.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):147-62 [12465600.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 [12463738.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Br J Cancer. 2003 Apr 22;88(8):1207-12 [12698185.001]
  • [Cites] J Clin Pathol. 1977 Jun;30(6):563-8 [874114.001]
  • [Cites] Nature. 1977 Jul 7;268(5615):69-71 [887150.001]
  • [Cites] Br J Cancer. 1978 Jun;37(6):1086-9 [307956.001]
  • [Cites] Br J Cancer. 1985 Jan;51(1):135-8 [3155620.001]
  • [Cites] Int J Cancer. 1985 Feb 15;35(2):199-205 [3918945.001]
  • [Cites] Int J Cancer. 1985 Oct 15;36(4):433-8 [3930410.001]
  • [Cites] Biochim Biophys Acta. 1986 Aug 5;865(1):27-41 [3524684.001]
  • [Cites] J Pathol. 1987 Aug;152(4):275-85 [3312546.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):3001-7 [2824022.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1039-45 [7734296.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):575-82 [7669564.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):818-23 [7547226.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):3-11 [8521614.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):85-94 [8558226.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3133-40 [8955659.001]
  • [Cites] Br J Cancer. 1997;76(6):805-11 [9310250.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):871-80 [9422744.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1535-41 [9508784.001]
  • [Cites] J Leukoc Biol. 1998 Sep;64(3):275-90 [9738653.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):44-8 [9988231.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):315-21 [10408832.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):585-92 [2156430.001]
  • (PMID = 16168111.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC1242127
  •  go-up   go-down


99. Tsai SL, Suk FM, Wang CI, Liu DZ, Hou WC, Lin PJ, Hung LF, Liang YC: Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis. Biochem Pharmacol; 2007 Dec 3;74(11):1575-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
  • In this study, we used the chemical drug 15,16-dihydrotanshinone I (DHTS) to inhibit breast cancer cell proliferation and tumor growth, and investigate the underlying molecular mechanisms.
  • Human breast cancer cell lines MCF-7 and MDA-MB-231 were both used in this study, and DHTS was found to significantly decrease cell proliferation by a dose-dependent manner in both cells.
  • Taken together, these results suggest that DHTS can inhibit human breast cancer cell proliferation and tumor growth, and might have potential chemotherapeutic applications.
  • [MeSH-major] Adenocarcinoma / prevention & control. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Breast Neoplasms / prevention & control. G1 Phase / drug effects. Phenanthrenes / pharmacology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17869226.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 15,16-dihydrotanshinone I; 0 / Antineoplastic Agents; 0 / Phenanthrenes; 0 / bcl-X Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 9007-43-6 / Cytochromes c; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


100. Witney TH, Kettunen MI, Hu DE, Gallagher FA, Bohndiek SE, Napolitano R, Brindle KM: Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate. Br J Cancer; 2010 Oct 26;103(9):1400-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate.
  • CONCLUSION: We show here that the early responses of a human breast adenocarcinoma tumour model to drug treatment can be followed by administration of both hyperpolarised [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate.
  • These techniques could be used, therefore, in the clinic to detect the early responses of breast tumours to treatment.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1999 Sep;52(3):225-32 [10580868.001]
  • [Cites] Med Phys. 2009 Nov;36(11):4870-7 [19994494.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2145-52 [11147583.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63 [12930897.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):721-32 [13130303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S103-11 [15103507.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S112-7 [15112111.001]
  • [Cites] J Histochem Cytochem. 1979 Jan;27(1):36-43 [220325.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3976-85 [8358726.001]
  • [Cites] Breast Cancer Res Treat. 1993;25(3):257-64 [8396465.001]
  • [Cites] Radiology. 1994 Jun;191(3):633-8 [8184039.001]
  • [Cites] Eur J Nucl Med. 1996 Oct;23(10):1409-15 [8781149.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] Biochem Pharmacol. 1999 Apr 1;57(7):727-41 [10075079.001]
  • [Cites] J Neurosci Res. 2005 Jan 1-15;79(1-2):216-23 [15562437.001]
  • [Cites] Biochem J. 2005 Feb 15;386(Pt 1):119-25 [15456408.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):121-34 [15693652.001]
  • [Cites] Semin Nucl Med. 2005 Apr;35(2):84-99 [15765372.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):913-7 [15829966.001]
  • [Cites] Cancer Imaging. 2005;5:27-31 [16154816.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Nov;6(6):821-9 [17140369.001]
  • [Cites] Biochim Biophys Acta. 2006 Dec;1766(2):242-61 [17140737.001]
  • [Cites] Exp Cell Res. 2007 Mar 10;313(5):867-77 [17289019.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1382-7 [17965722.001]
  • [Cites] Invest New Drugs. 2008 Feb;26(1):1-5 [17628743.001]
  • [Cites] Nat Rev Cancer. 2008 Feb;8(2):94-107 [18202697.001]
  • [Cites] Dis Esophagus. 2008;21(2):151-8 [18269651.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Magn Reson Med. 2008 Aug;60(2):253-7 [18666104.001]
  • [Cites] Eur J Cancer. 2009 Jan;45(2):228-47 [19097774.001]
  • [Cites] Neoplasia. 2009 Jun;11(6):574-82, 1 p following 582 [19484146.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19801-6 [19903889.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):880-6 [10741711.001]
  • (PMID = 20924379.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C197/A3514; United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Isotopes; 0 / Fumarates; 5921X1560Q / Calcium Dobesilate; 8558G7RUTR / Pyruvic Acid
  • [Other-IDs] NLM/ PMC2990617
  •  go-up   go-down






Advertisement